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The mostly used chemotherapy regimens in the treatment of malignant lymphomas 
 
Hodgkin’s lymphoma 
ABVD: doxorubicin, bleomycin, vinblastine, dacarbazine 
BEACOPP: bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, 
prednisone 
ChlVPP: chlorambucil, vinblastine, procarbazine, prednisone 
EBVP: epirubicin, bleomycin, vinblastine, prednisolone 
MIME: mitoguazone, ifosfamide, methotrexate, etoposide 
MOPP: nitrogen mustard, vincristine, procarbazine, prednisone 
MVPP: nitrogen mustard, vinblastine, procarbazine, prednisone 
OPPA: vincristine, procarbazine, prednisone, doxorubicin 
OEPA: vincristine, etoposide, prednisone, doxorubicin 
 
Non-Hodgkin’s lymphoma  
Chlorambucil 
CHOP: cyclophosphamide, doxorubicin, vincristine, prednisone 
CVP: cyclophosphamide, vinblastine, prednisone 
ENAP: mitoxantron, cytarabin, etoposide, prednisone 
MACOP-B: methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone, 
bleomycin 
MIME: mitoguazone, ifosfamide, methotrexate, etoposide 
 
 
High dose therapy with autologous stem cell support  
Conditioning regimens used for both Hodgkin’s and Non-Hodgkin’s lymphomas: 
Total Body Irradiation (TBI) with high dose cyclophosphamide until 1995 
BEAM: carmustine, etoposide, cytarabine, melphalan used from 1995 
BEAC: carmustine, etoposide, cytarabine, cyclophosphamide in 1995 
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2. Introduction 
 
 During the last two decades the number of cancer survivors in the Western world has 
been steadily increasing. Estimates from the National Cancer Institute (United States) show 
that the numbers of cancer survivors now exceeds 12 million people in the United States 
(NCI, 2009). In Norway, there are more than 180 000 people living with or after a cancer 
diagnosis (1). The growing numbers of cancer survivors is explained by increasing cancer 
incidence, improved diagnostic procedures and the use of more effective treatment modalities 
with improved survival rates. Currently, about 60% of cancer patients live for more than five 
years (1). 
 Cancer survivorship was first introduced as a concept in 1985 (2), and three phases of 
cancer survivorship was described: acute survival (from diagnosis to the completion of 
primary treatment), extended survival (remission of the disease, including follow-up 
examinations and eventual treatment for relapse) and permanent survival (evolves from 
extended disease-free survival when the likelihood for recurrence is low) (2;3). Usually, long-
term cancer survivors are defined as those living more than five years after initial diagnosis 
(3). 
 There has been an increasing interest for the field of cancer survivorship over the last 
years, even though this is still regarded as a new area of research within oncology. 
Chemotherapy, radiotherapy and surgery, alone or in combination, may lead to long-term 
adverse health effects, and cancer survivors are at increased risk of various medical and 
psychosocial complications after treatment (4;5). Overall, the goal of cancer survivorship 
research is to study the health and quality of life of patients treated for cancer beyond the 
phase of diagnosis and primary treatment, and seek to prevent and treat adverse late effects 
(3).  
 This thesis concerns late adverse health effects after treatment for malignant 
lymphomas, namely Hodgkin’s lymphoma (HL) and Non-Hodgkin’s lymphoma (NHL). 
According to the Norwegian Cancer Registry there lived 7961 survivors of malignant 
lymphoma in Norway by the end of 2007 (1). As an oncologist I have taken a particular 
interest in the issues of survivorship after treatment for malignant lymphoma, and this thesis 
consists of four studies on various aspects of late effects after both HL and NHL. First, an 
introduction to these diseases and their treatment will be given. 
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3.  Background 
3.1. Malignant lymphomas: incidence – prevalence – treatment 
 The incidence of HL in Norway has been stable the last 50 years, and in 2007, there 
were 114 new cases (64 males, 50 females) (1). For NHL the incidence has been steadily 
increasing, and in 2007 there were 797 new cases of NHL (418 males, 379 females) in 
Norway (1). A total of 1989 persons were alive in Norway by the end of 2007 with a previous 
diagnosis of HL, the comparable number for NHL being 5972 (Table1). Of these, 1063 
persons had lived for more than 10 years after the diagnosis of HL and 1896 after the 
diagnosis of NHL (1). The five year relative survival for patients diagnosed with HL in 1998-
2002 was 91% for males and 89% for females, with the comparable numbers for NHL being 
58% for males and 61% for females (1). 
 
   
Type of lymphoma Total <1  year  
 
after 
diagnosis 
1-4 years  
 
after 
diagnosis 
5-9 years  
 
after 
diagnosis 
10+ years  
 
after 
diagnosis 
 
N    n    n n   n   
Hodgkin’s lymphoma 1989  109  415 402 1063 
Non-Hodgkin’s lymphoma 5972  683 1990 1403 1896 
Total 7961  792 2405 1805 2959 
Table 1. Number of Norwegian survivors of HL and NHL by the end of 2007 according to the Norwegian 
Cancer Registry related to years after diagnosis. 
 
 
 HL is a disease mainly affecting young adults, and with the excellent survival rate, 
most of the patients treated for HL have a long life-expectancy. Therefore, long-term toxicity 
and psychosocial complications in HL survivors are important to investigate, and it also 
makes this group suitable for long-term follow up studies.  
 NHL is a heterogeneous group of diseases that for the purpose of this overview may 
be divided in indolent, aggressive and very aggressive forms. For NHL age at diagnosis is 
higher than in HL, and NHL comprises heterogeneous subgroups with different treatment 
recommendations over time. In Norway, the incidence and prevalence registrered by the 
Cancer Registry is usually given for the whole group of NHL, and the prognosis for the whole 
group is not as favorable as for HL. Therefore, among survivors after malignant lymphomas, 
 10
most studies on long-term effects after treatment have been performed in HL survivors, with a 
more scarce literature available on survivorship after NHL. 
 
Treatment strategies for HL at the NRH in the period 1970 – 2007 
 The treatment strategies for HL at the Norwegian Radium Hospital (NRH) have 
followed national and international guidelines, and are summarized in Table 2 for the period 
1970-2007. 
Limited disease - stage I and II 
From 1970 – 1997 mantle field and inverted-Y field radiotherapy dominated in stage 
I/II patients given alone or after chemotherapy (6;7). If possible, the standard inverted-Y field 
was modified (to unilateral L-field or para-aortic field) in order to reduce the doses. Gonadal 
shielding was routinely used, reducing gonadal doses from 0.6 to 0.1–0.2 Gy during mantle 
field irradiation. Inverted-Y field resulted in testicular doses of 0.6–0.9 Gy. In the 1970’s, 
medial transposition of the ovaries in order to protect them, was offered to young patients. In 
these patients, the shielded ovaries received about 3 Gy when treated with inverted-Y field 
(Jetne, NRH, 1972, unpublished data). Radiotherapy was fractionated as 2 Gy x 20 from 1970 
and 1.8 Gy x 23 from 1982.  
From 1997 the radiation fields were limited to modified involved fields (including the 
affected lymph node with 5 cm craniocaudal margine) and the dose was reduced to 1.75 Gy x 
17-20 in order to reduce long-term adverse effects. 
From 1980 two - four courses of chemotherapy were given to patients with risk factors 
at diagnosis before irradiation. In the period 1980-88 chemotherapy was given as 
MOPP/MVPP/ChlVPP (8), and as EBVP in the period 1988-1997. ABVD/ABOD has been 
the standard chemotherapy regimen for patients with stage I/II from 1997 and as ABVD from 
1997 (without risk factors 2 courses, with risk factors 4 courses) (9-12).  
Risk factors in 1980-1997 were: large mediastinal tumor, bulky disease, involment of 
> three lymph node sites above diaphragm, B-symptoms, infradiaphragmatic disease, 
lymphocyte depleted type. Risk factors from 1999 were (for supradiaphragmatic disease) at 
least one of the following: bulky disease,  three involved sites, erethrocyte sedimentation 
rate (ESR)  50, involvement of two not neighbour localications. Risk factors for 
infradiaphragmatic disease were at least one of the following: pelvic localization, stage IIA, 
bulky disease, inguinal disease IA and ESR  50 (combined)(13). 
 
 
 11
Advanced disease - stage III and IV 
As a general strategy from 1970, stage III and IV patients were treated with 6-8 
courses of chemotherapy supplemented with radiotherapy to sites of bulky tumor or residual 
masses. In the period 1970 – 1980 some stage III patients received total nodal irradiation 
(TNI: mantle and inverted-Y field, 2Gy x 20), but TNI was abandoned from 1980.  
Chemotherapy was given as MVPP / ChlVPP until 1985 (8). From 1985 to 1990, primary 
chemotherapy with MVPP/ChlVPP was gradually replaced by ABOD or EBVP (14) and in 
the period 1992-98 chemotherapy has been given as 8 courses of ABVD. From 1999 
chemotherapy was given as 6-8 ABVD for patients with an International Prognostic Score 
(IPS) 0-3, whereas the BEACOPP regimen was used if IPS score 4-7 (15).  The seven 
parameters defining the IPS for advanced HL are: serum albumin<4g/dl, hemoglobin<10.5 
g/dl, male sex, stage IV disease, age  45 years, white cell count 15 000/mm3, lymphocyte 
count <600/mm3 or <8 % of white cell count (16) . 
The radiotherapy was fractionated as 2 Gy x 20 until 1985, as 2 Gy x 20 or 1.8 Gy x 23 until 
1998, and as 1.75 Gy 17-20 from 1997. 
At relapse, patients have been treated with non cross-resistant chemotherapy or from 
1990 with high-dose chemotherapy with autologous stem cell support (HDT) in case of early 
relapse. HDT consisted of fractionated total body irradiation (TBI) combined with high-dose 
cyclophosphamide until 1995 and thereafter of chemotherapy only (BEAC/BEAM) (17;18).
   
 
 
Figure showing gonadal shielding in males during inverted-Y field irradiation. 
Figure copied from radiotherapy protocol for HL at the NRH 1976. 
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Table2. 
Treatment of HL at the NRH 1970-2007. 
 
 
 
Chemotherapy 
 
 
Radiotherapy (RT) 
 
Dose and fractions of 
radiotherapy 
 
Stage I & II 
 
   
1970-80 
 
 Extended field RT 
(MF / Inv Y) 
2 Gy x 20 
1980-88 With risk factors:  
4 MVPP/ChlVPP 
before RT 
 
Extended field RT 
(MF /Inv Y) 
2 Gy x 20,  
from 1982 1,8 Gy x 23 
1988-97 With risk factors:  
2-4 EBVP 
before RT 
 
Extended field RT 
(MF/Inv Y) 
 
1,8 Gy x 23 
1997-2007 
 
No risk factors: 2 ABVD 
With risk factors: 4 
ABVD 
Modified involved field  
  
1,75 Gy x 17 -20 
 
Stage III & IV 
 
   
1970-80 
 
8 MVPP/ChlVPP III: MF+InvY (TNI) 2 Gy x 20 
1980-1985 8 MVPP/ChlVPP To sites of initial bulky 
tumor or residual mass 
 
2 Gy x 20 
1985-1991 8 ChlVPP or  
8 ABOD/ChlVPP 
(alternating) 
 
To sites of initial bulky 
tumor or residual mass 
2 Gy x 20 or 
1,8 Gy x 23 
1992-1998 8 ABVD To sites of initial bulky 
tumor or residual mass 
 
2 Gy x 20 or 
1,8 Gy x 23 
1999-2007 
 
 
 
IPS2 0-3 6-8 ABVD 
 
IPS 4-7 
 2 escalated BEACOPP + 
6 standard BEACOPP 
 
To bulky tumor or residual 
mass 
 
1,75 Gy x 17-20 
Abbreviations:  
MF: Mantle field  
Inv Y: Inverted Y field 
TNI: Total nodal irradiation 
Risk factors and IPS explained in text. 
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Extended radiation fields used for HL 
 
 
 
 
 
 
 
 
from: www.med-ed.virginia.edu/.../wcd/hodgclinic.cfm 
 
Example of modified involved radiation fields used for HL 
 
 
 
 
 
 
 
 
 
Pictures provided by A. Fosså. 
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Treatment strategies for NHL at the NRH 1980 – 2002. 
 The treatment strategies for NHL at the NRH have followed national guidelines, and 
are summarized in Table 3 for the period 1980-2002.  
 Indolent NHL localized disease (stage I, early stage II disease) has been treated with 
radiotherapy only (fractionated as 2 Gy x 15) as curative treatment (19).  
 Advanced disease has been and to a large extent still is regarded as incurable (20;21)  
and in asymptomatic patients initial therapy may be postponed (watchful waiting). Indolent 
lymphomas are sensitive to several chemotherapeutic drugs (21). Indolent NHL has 
traditionally been treated with Chlorambucil alone at the NRH, with repetition of this 
treatment in case of relapse. Other chemotherapy regimens have also been possible options, 
such as CHOP and CVP. From year 2000, Rituximab, either alone or combined with 
chemotherapy, or interferon-alpha has been used for CD20 positive lymphomas (22). 
Radiotherapy has mainly been used as as palliation for local symptomatic disease in patients 
with advanced stages (typically fractionated as 2 Gy x 15). 
 At early relapse or after several cycles of Chlorambucil, CVP or CHOP chemotherapy 
have been used. Alternatively, for younger patients MIME (23) has been used at relapse after 
CHOP, especially as induction chemotherapy before HDT. ENAP has been used at relapse in 
the elderly patients (24).  
 Aggressive NHL, localized disease, was until 1990 treated with radiotherapy only, 
from 1990 treated with CHOP based chemotherapy followed by irradiation. Radiotherapy has 
been given to involved fields only, typically 2Gy x 20.  
 Advanced disease has traditionally been treated with CHOP-based chemotherapy, 
combined with consolidating radiotherapy to sites of initial bulky disease or residual masses 
after chemotherapy. At relapse non-cross resistant chemotherapy has been given, mostly as 
MIME for the younger patients and ENAP for the elderly. From the beginning of the 1990’s 
HDT has been offered in second remission using the same conditioning regimens as for HL. 
For aggressive T-cell lymphoma and mantle cell lymphoma in younger patients, HDT has 
been given as consolidation therapy in first remission from year 2000. Rituximab has been in 
use from about 2004 for CD-20 positive lymphomas. 
 Very aggressive NHL in the form of Burkitt- and Burkitt-like lymphomas were in the 
1980’s treated with CHOP chemotherapy combined with high dose methotrexate 
intravenously and intrathekal (CHOPmM). From 1987 this regimen was followed by HDT in 
younger patients responding to CHOP. From 1995 treatment has been given according to 
BFM / GMALL protocols (25). Lymphoblastic lymphomas were initially treated with 
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CHOPmM, with HDT offered to younger patients in first remission from 1987. From 1992 
the induction treatment has been given according to leukemia-protocols (26;27). From about 
2006 Rituximab has been given in combination with chemotherapy if CD20 positivity also in 
very aggressive lymphomas. Radiotherapy has had a minor role in the treatment of very 
aggressive NHL, but has to some extent been used according to the guidelines in aggressive 
forms of NHL. 
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Table3. Treatment strategies of NHL 1980-2002 
 
NHL 
 
 
Primary treatment 
 
 
Relapse treatment 
 
Localized disease  
(stage I, early stage II) 
RT only (2Gy x 15) 
 
Indolent 
lymphomas 
 
 
Advanced disease 
Whatcful waiting 
Chlorambucil 
CVP* 
CHOP* 
Rituximab ± Interferon-alpha 
 
Watchful waiting 
Chlorambucil 
CVP*  
CHOP* 
ENAP* to elderly patients 
MIME* to younger patients alone or as induction before 
HDT 
HDT for chemosensitive disease at first or subsequent 
relapse or after transformation 
 
 
RT for local symptomatic disease (2 Gy x 15) 
Localized disease  
 
1980-1990 
(Stage I, early stage II) 
RT only  (2Gyx20) 
 
1990 -  
CHOP* based chemotherapy 
followed by RT (2Gyx20) 
 
 
Aggressive 
lymphomas 
Advanced disease 
 
CHOP* based chemotherapy 
 
T-cell lymphomas / Mantle cell 
lymphomas 
 
HDT in 1. remission from 2000 
 
RT if residual mass or initial bulky 
disease (2 Gy x 20) 
 
 
 
 
 
 
 
 
Non-cross resistant chemotherapy 
MIME* in the younger 
From 1990: HDT in 2.remission 
ENAP* in the elderly 
 
 
 
Burkitt lymphomas: 
Until 1995: 
CHOP with Mtx i.t. and high dose 
Mtx iv. (CHOPmM)  
1987 - 1995  
HDT in first remission 
 
1995 - 
BFM / GMALL protocols  
 
Very aggressive 
lymphomas 
 
 
 
Lymphoblastic lymphomas 
 
until 1992: CHOPmM 
1987 - 
HDT in first remission 
 
1992 – 
Leukemia protocols **  
 
RT: Radiotherapy. HDT: High dose chemotherapy with autologous stem cell support. 
*:Rituximab used in CD20 positive indolent NHL from about 2000, and in CD20 positive aggressive – and very 
aggressive lymphomas from 2004. 
** Leukemia-protocols for lymphoblastic lymphomas: LSA2L2:1992-1997, Hammersmith: 1997-. 
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3.2.  Long-term adverse effects after treatment for malignant lymphoma 
 Some of the long-term adverse effects after treatment for malignant lymphoma may be 
severe and even life-threatening, like second cancers and cardiovascular diseases (28-32). 
Other late effects, like infertility, hormonal disturbances and fatigue (33-42) need not be life-
threatening, but may nevertheless have significant impact on the survivors’ health and quality 
of life. An overview of the long-term adverse effects most relevant for this thesis will now be 
given. 
 
Mortality  
 Previous studies have shown that patients treated for HL have increased mortality 
when compared to expected mortality in the general population (28;31;43;44). These studies 
have explored the standardized mortality ratio; the ratio between the observed deaths in the 
cohort and the expected number of deaths if the cohort had the same mortality rate as the 
general population (28;31;43;44). The mortality in HL patients later than 10 years after 
treatment is only explored in a few studies (28;31). The study including the largest sample of 
HL survivors (n= 4401) reported the standardized mortality rate to be 7.4 at a median follow-
up of 7.8 years (44). A comparable figure was found in a survey of 1261 HL survivors treated 
before the age of 41 years in the period 1965-1987 (median follow-up time 17.8 years), with a 
6.8 times higher relative risk (RR) of death from all causes other than HL compared to the 
general population (28). The RR of mortality from all causes has been shown to remain 
significantly elevated more than 20 years after treatment for stage IA - IIB HL (31). The most 
common causes of deaths are reported to be relapse of HL, second cancers, cardiovascular 
diseases and infections (28;31). Mortality after treatment for NHL has been studied in the 
Childhood Cancer Survivors Study, which reported elevated death rates from solid tumors, 
leukemia, cardiovascular diseases and pneumonia compared to US population rates (45).  
   
Second malignancies 
  Second malignancies after treatment for HL may appear as leukemia, NHL or solid 
tumors (46). The increased risk of leukemia following treatment for HL has been related to 
the use of alkylating agents (47), with the highest risk for reported to be 2-10 years after 
primary treatment, and the prognosis is considered to be poor (31;46). 
 An elevated risk for development of NHL after the treatment for HL has also been 
observed (31;48). Such development may be treatment induced, but may also be seen as the 
natural course of HL (46). Another explanation may be changes in histopathological 
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classification. Some lymphomas earlier classified as HL, especially of the lymphocyte 
depleted and unclassified subtypes in the elderly (considered to be associated with poor 
prognosis), may at relapse have been classified as NHL (49). 
 Solid tumors account for almost 80% of all cases of second malignancies after HL, 
and they typically develop after a latency of more than 10 years after treatment, with 
incidence curves increasing with longer observation time (30;31;48;50-52). Breast -, lung- 
and gastrointestinal cancer are the most frequently observed secondary solid tumor after HL 
(30;31;48;50-52), and the elevated risk has been associated with radiotherapy treatment (52-
54). After chemotherapy, an increased lung cancer risk has been reported after treatment with 
alkylating agents (50;53;55). 
 Also after treatment for NHL an increased risk of subsequent second malignancies has 
been reported (56-58).  
 
Cardiovascular diseases 
  There is an elevated risk of cardiovascular complications after treatment for HL 
including coronary artery disease, valvular disorders, ventricular dysfunction and congestive 
heart failure (29;59-63). Mediastinal radiotherapy increases the risk of valvular disorders, 
coronary heart disease and congestive heart failure (29;61;62). Chemotherapy, especially 
anthracyclines, may induce cardiomyopathy and may further elevate the risk of coronary heart 
disease in combination with mediastinal radiotherapy (29;64;65). Increased risk of cardiac 
mortality after treatment with chemotherapy for HL has been reported in recent years (62;66).   
 After treatment of both HL and NHL, doxorubicin-associated cardiomyopathy and 
congestive heart failure have been shown to be dose dependent (65;67). Adult patients 
receiving cumulative doses of doxorubicin not exceeding 500-550 mg/m2 of body surface are 
considered to have a relatively low risk for developing cardiomyopathy (65;67). However, 
even after treatment with doxorubicin in lower doses (median dose doxorubicin 300mg/m2 ) 
for NHL, subclinical cardiomyopathy has been reported in almost one third of the patients 
more than five years after treatment (68).  
 
Gonadal dysfunction  
 Gonadal dysfunction may be classified as primary and / or secondary. Primary 
hypogonadism is due to testicular or ovarian damage, i.e. after intensive chemotherapy or 
irradiation to these organs. Secondary hypogonadism is caused by damage to the pituitary 
gland or hypothalamus, i.e. after cranial radiotherapy. Gonadal dysfunction may result in 
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impaired spermatogenesis and / or dysfunction of the Leydig cells in males and premature 
ovarian failure in females, with infertility, hormonal disturbancies and reduced sexual 
function as potential consequences. 
 Hormonal disturbances and infertility may not be life-threatening, but may cause 
psychological distress and reduced quality of life (69-71). Male hypogonadism and premature 
menopause in females may, if not substituted, contribute to serious somatic diseases as 
arteriosclerosis and osteoporosis (72-76). Since studies of gonadal function in males treated 
for HL and NHL (paper 2) and post-treatment parenthood in both sexes after treatment for HL 
(paper 4) are included in this thesis, studies of gonadal function after treatment for malignant 
lymphomas will be considered in some detail. 
 
Female gonadal function / dysfunction 
 At birth, the normal female ovary contains about 1-2 million oocytes. By the time a 
girl enters puberty, only about 25% of her total egg pool remains, around 300,000. After a 
progressive decrease, there remains 400 follicles at the time of menopause (77).  
 Chemotherapy and radiotherapy may result in reduced follicle count and ovarian 
atrophy, with premature ovarian failure (POF) as a result (78). Regular menstruation post-
treatment can be assessed by asking the patients, but does not equal possibility of pregnancy 
due to the risk of anovulatory cycles. POF (defined as persistent amenorrhea before the age of 
41) was found in 37% of female HL survivors (n=99), with increased risk after treatment with 
chemotherapy in addition to radiatiotherapy (79). Secondary amenorrhea has been reported to 
be more frequent in women older than 30 years at treatment for HL compared to younger 
women, and after more intensive chemotherapy (37).  
 
Male gonadal function / dysfunction 
 Testicular damage caused by chemotherapy and / or irradiation may result in elevated 
follicle stimulating hormone (FSH) as an indication of impaired spermatogenesis, whereas 
permanently elevated luteinizing hormone (LH) indicates Leydig cell dysfunction. Secondary 
hypogonadism caused by damage to the pituitary gland or hypothalamus may lead to 
decreased LH and FSH followed by both exocrine and endocrine gonadal failure. Male 
gonadal function can be screened for by assessment of serum levels of LH, FSH, testosterone, 
sex-hormone binding globuline (SHBG), sperm cell count and by documentation of 
fatherhood. 
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 Some studies have shown that pre-treatment spermatogenesis in HL patients is more 
impaired than in NHL patients (80-82), which indicates that there might be factors specific for 
HL that impairs spermatogenesis more than in NHL patients. 
 Post-treatment spermatogenesis in male malignant lymphoma survivors is dependent 
on the type of chemotherapy, the drugs’ cumulative dose, the radiation dose to the testicles 
from scattered or direct irradiation, and the time since treatment (42;83). Alkylating agents 
(cyclophosphamide, ifosfamide, chlorambucil, nitrosureas, melphalan, busulfan and 
procarbazine) appear to be the most gonadotoxic cytostatic drugs. After treatment with 
MOPP-like chemotherapy for HL, long-lasting impaired spermatogenesis is observed in about 
90% of the patients, whereas only about 10% of the males become permanently infertile after 
ABVD-like regimens (42;84). Elevated FSH in was found in 35% of male HL survivors at a 
median observation time of 32 months after treatment for early stage upper-diaphragmatic 
disease with radiotherapy with or without chemotherapy (n=355) (85). The probability of 
elevated FSH increased after treatment with alkylating agents, age above 50 years at treatment 
and stage II compared to stage I disease. After treatment with CHOP-like chemotherapy for 
NHL, recovery of spermatogenesis to normal levels can be expected in about two thirds of the 
patients (86).  
 The sperm cells are very radiosensitive, and the damage of the gonads after 
radiotherapy is dose-dependent. Recovery of spermatogenesis can be expected after 9-18 
months after radiation doses of 1 Gy or less to the testicles, 30 months after a dose of 2-3 Gy 
and 5 years or more for doses of 4 Gy and above. Radiation doses of  4 Gy and above may 
result in permanent azoospermia (87;88). 
 During recent years evidence has emerged that male survivors after malignant 
lymphoma also may have subnormal serum levels of testosterone and / or elevated LH 
(40;75;89;90).  
 Most studies on post-treatment gonadal function in male lymphoma survivors have 
assessed spermatogenesis measured by sperm cell count and / or the level of serum FSH, with 
some reports on Leydig cell damage.  Most of these previous studies have been performed in 
limited series of HL survivors. Studies assessing both endocrine (LH/testosterone) and 
exocrine (measured as FSH) gonadal function in a large sample of male survivors after 
treatment for both HL and NHL, treated with different chemotherapy regimens, have been 
lacking so far.  
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Sexual function in malignant lymphoma survivors  
 Sexual dysfunction may be a distressing late-effect after cancer treatment (71), and a 
survey assessing information needs in NHL survivors of both sexes showed that 28% wanted 
information about sexual functioning (91).  
 In a survey on long-term effects after treatment for HL performed at the NRH in 1994, 
16% of the survivors of both sexes reported transient and 12% reported long-term sexual 
problems (35). Similar figures have been reported by other studies on sexual function also 
including both male and female HL survivors; 24% reported at least one sexual problem 
attributed to having had cancer (92), and sexual interest and activity had decreased in about 
20% of HL survivors compared to their pre-treatment situation after a median duration of 
follow-up of  9 years  (93).  
 In studies including only males, approximately 30% of survivors after malignant 
lymphoma and testicular cancer reported one or more sexual dysfunctions (94). This 
proportion is similar to that observed in the general male population (95). However, when a 
standardized questionnaire on erectile function was used, reduced erectile function was 
reported by 61% (36/59) of male lymphoma survivors aged 18-55 years (96), which is more 
than what is observed in the general male population. This may indicate that the prevalence of 
self-reported sexual problems may be higher when more extensive and detailed questionnaires 
are used. 
 Only few studies on sexual function in male lymphoma survivors have so far assessed 
sexual function with standardized questionnaires and none of them have included controls 
from the general population. When assessing sexual function in cancer survivors, the use of a 
comparison group from the general population is of great importance, because sexual 
dysfunction is prevalent also among men in the general population, with the prevalence 
increasing with ageing (95;97;98). We therefore are in need of more studies that fulfil these 
methodological requirements. 
 
Parenthood after treatment 
 Most previous studies on fertility in HL survivors have examined post-treatment 
spermatogenesis in males and secondary amenorrhea in females (37;42;99). Although the 
number of achieved pregnancies and childbirths is sometimes reported in small series 
(90;100-103), only few reports have taken into consideration the proportion of survivors 
attempting parenthood (36;104). Adult childhood cancer survivors (among others treated for 
HL or NHL) reported less frequently birth of biological children compared to a control group, 
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with the controls selected among patients from the patient lists of  the survivor’s regular GPs 
(105).  
 To counter for the risk of reduced post-treatment spermiogenesis, Norwegian male 
cancer patients have had the option for pre-treatment semen cryopreservation since 1980. 
However, studies of male cancer survivors have shown that less than 15% of them use their 
pre-treatment cryopreserved semen in order to obtain post-treatment paternity (106;107). In 
Norway, assisted reproductive techniques have been offered and performed as intrauterine 
insemination (IUI) in the early 1980s, in vitro fertilization (IVF) since 1988, and 
Intracytoplasmatic sperm injection (ICSI) has been offered since 1995. Pretreatment 
cryopreservation of fertilised oocytes has been a possible option since 1988, but in such cases 
the female patient has to delay startup of cancer treatment for several weeks in order to obtain 
mature oocytes. Since 2004 pre-treatment preservation of ovarian tissue has been a legalized 
opportunity in Norway, but this procedure is still considered to be experimental. Until now, 
no child has been born in Norway with use of this method. Use of donated semen is legalized, 
whereas use of donated oocytes is not.   
 For many of the young adult survivors after malignant lymphomas the struggle for 
post-treatment parenthood becomes an important dimension of their quality of life (5), though 
the exact percentage of the Norwegian HL survivors who plan and achieve post-treatment 
parenthood, with or without assisted reproduction techniques, has remained unknown. It is 
well-known that such struggles might be a considerable stress for the couple (108). 
 
Health related quality of life  
 Health related quality of life (HRQoL) is a multidimensional concept that refers to an 
individual’ usual physical, emotional and social well-being (109). This has been self-reported 
by the patients by using stardardized questionnaires. Compared to a normative sample 
representative for the general Norwegian population HL survivors reported poorer HRQoL at 
a median of 12 years after diagnosis, mainly on physical health (110), and higher prevalence 
of anxiety (111).  
  
Fatigue 
 Fatigue can be defined as “a persistent feeling and subjective sense of tiredness that 
interferes with usual functioning” (112). Fatigue lasting for more than six months has been 
defined as chronic fatigue (CF) (113). The first study on fatigue in HL survivors was 
published in 1986 where 37% stated that their energy level had not returned to normal at a 
median follow-up of 9 years after treatment (93). Later studies have shown that HL survivors 
 23
have increased levels of fatigue compared to the general population (41;114;115). A cross-
sectional questionnaire survey in 1994 on late adverse effects in 557 HL survivors treated at 
the NRH, 26% reported CF compared to 11% in a sample of the general Norwegian 
population (41). There was no significant associations between CF and type of primary 
treatment, and the prevalence of CF seemed stable in spite of the introduction of less toxic 
treatment regimens (41;116). A significant association between late pulmonary sequelae and 
CF was observed (117), while no significant association were observed between cardiac 
sequelae and CF. A significant association between CF and B-symptoms (night sweats, fever 
of unknown cause, weight loss) has been demonstrated (41;116).  
 In contrast to psychological distress, sexuality and QoL, fatigue is among the more 
researched issues in survivors of HL with high methodological quality of most studies. 
However, the mechanisms underlying CF in HL survivors still remain unclear (118). One 
might speculate whether CF in HL survivors reflects aspects of the disease itself such as 
persistently altered cytokine levels or immune dysfunction both stimulating low-grade 
inflammatory processes which may lead to fatigue of variable durations.  
 It is not known whether CF in cancer survivors predicts reduced somatic health 
outcomes in the future, and to our knowledge, no study has investigated the possible 
association between CF and future significant health events such as mortality in cancer 
survivors.  
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4. Aims of this thesis 
 Overall, the aims of this thesis were to examine selected aspects of survivorship after 
treatment for malignant lymphomas in both males and females, with emphasis on mortality 
and causes of deaths (Part I), male endocrine hypogonadism and sexual function, and fertility 
in both males and females (Part II).  
The specific aims were: 
 
Part I  
Mortality and causes of deaths among  3 years survivors after HL  
(Paper1) 
  
• To analyse mortality and causes of death in a cohort of  3 years survivors after 
treatment for HL compared to controls from the general population matched for age 
and gender. 
Hypothesis: HL survivors have increased mortality compared to age and gender matched 
controls from the general population. 
 
• To explore if  HL survivors identified with chronic fatigue (CF) in a previous survey 
have increased mortality compared to HL survivors without CF  
Hypothesis: CF in HL survivors is associated with increased mortality. 
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Part II 
A: Male gonadal - and sexual function after treatment for malignant lymphoma  
(Paper 2 and 3) 
 
• To assess the prevalence of post-treatment gonadal dysfunction in male lymphoma 
survivors in relation to age and treatment. 
Hypothesis: Endocrine gonadal dysfunction in male lymphoma survivors is associated with 
increasing age and treatment intensity. 
 
• To examine sexual function in male lymphoma survivors as compared to that of age 
matched controls from the general population and to examine factors associated with 
reduced sexual function in male lymphoma survivors. 
Hypothesis:  Sexual function is decreased in lymphoma survivors as compared to males in the 
general population, and is associated with increasing age and endocrine testicular function in 
the lymphoma sample. 
 
 
B: Fertility, as post-treatment parenthood, in male and female HL survivors  
(Paper 4) 
 
• To determine rates of attempted and achieved post-treatment parenthood in HL 
survivors related to age and treatment.  
Hypothesis: Attempts of post-treatment parenthood in HL survivors are associated with age at 
diagnosis. Achievment of post-treatment parenthood, among those who have attempted to 
become this, is associated with treatment intensity in both genders. 
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5. Patients and Methods 
5.1. Study populations 
 
Selection of patients 
The Lymphoma database at the Norwegian Radium Hospital 
 The Lymphoma database at the NRH was established in 1980 and contains relevant 
data on all lymphoma patients referred to the hospital, for HL from 1970 and for NHL from 
1980. For each patient, information on diagnostic parameters such as stage at diagnosis, 
chemotherapy and radiotherapy treatment and relapses in addition to date of eventual death is 
recorded. A total of 2428 HL patients (n = 1206 alive) and 6621 NHL patients (n = 2534 
alive) are registered in the lymphoma database at the NRH (date for search November 25. 
2009). In the studies included in this thesis, medical and treatment data on each patient was 
extracted from the Lymphoma database. See figure below. 
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The Lymphoma database at the Norwegian Radium Hospital 
HL registered from 1970, total n = 2428 (n = 1206 alive) (November 25, 2009) 
NHL registered from 1980, total n = 6621 (n = 2534 alive) (November 25, 2009) 
 
1994 
Questionnaire survey 
 
HL males and females 
Diagnosis 1971-1991 
Age at diagnosis: 15-61 
Total eligible n = 557 
 
 
 
2001 / 2002 
Questionnaire survey 
 
HL males and females 
Diagnosis 1971-1998 
Age at diagnosis: 9-62  
Total eligible n = 602 
 
 
 
2007 
Questionnaire survey and 
gonadal hormones assessed 
HL / NHL males 
Diagnosis 1980-2002 
Age < 50 years at diagnosis 
Total eligible n = 653 
 
 
 
Followed in time 
from 1994 
To death or  
Jan 1st 2007 
Mortality and causes 
of death recorded 
 
 
Paper 1 
Paper 2 and 3 Paper 4 
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Patients Paper 1 
 This study was a follow-up investigation of a previously described patient cohort from 
a survey on late-effects after treatment conducted in 1994 (41;110;111), but in the current 
study with mortality and causes of death as end-points. The eligibility criteria for the 1994-
survey were HL survivors treated at the NRH from 1971 - 1991, aged 15 - 61 years at 
diagnosis and aged 19 - 74 at the time of the survey, alive and in complete remission by the 
end of 1993 (35). A total of 557 patients were contacted by mail, and 459 (82%) returned 
filled-in questionnaires.  
 Of the 557 HL survivors who were approached in 1994, 43% were female and almost 
80% were treated with mediastinal radiotherapy with or without chemotherapy. Median age at 
diagnosis was 30 years (range 15-60), and median age at survey in 1994 was 43 years (range 
19-74). The median time from diagnosis to the 1994-survey was 12.2 years (range 2.3-23.0 
years). Fatigue, and in particular CF, was assessed by the Fatigue Questionnaire (FQ), vide 
infra (119).  
 Based on the findings in the 1994-survey the patients were categorized in three 
groups: 1: participants without CF (n= 329)  
  2: participants with CF (n=113) 
   3: non-participants who did not return the questionnaire (n = 98).  
   
Patients Paper 2 and 3. 
 In 2007 a cross-sectional survey was performed among male lymphoma survivors, 
including measurements of serum gonadal hormones (testosterone, SHBG, FSH, and LH) and 
a questionnaire assessing various aspects of quality of life (QoL). Only male survivors were 
included because a study on POF in female HL survivors had recently been published by our 
group (79). 
 The eligibility criteria for the survey were: male patients  50 years at diagnosis, 
treated for HL or NHL, diagnosed in the period 1980 – 2002, age above 18 years at the time 
of the survey, alive in June 2007 and having a valid postal address. Patients treated with total 
brain or scrotal irradiation was excluded. A total of 653 male patients met the inclusion 
criteria and were contacted by mail (360 HL survivors, 293 NHL survivors). Observation time 
was calculated from date of diagnosis to January 1st 2007, and was further categorized in 
three groups: 1: 4–10 years, 2: 11–20 years, 3: 21–28 years. 
 Paper2: Of the 653 male lymphoma survivors, 294 (45%) had their gonadal hormone 
levels assessed and were included in the study of gonadal hormones. 
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  The compliers (with assessed serum gonadal hormones) were older both at diagnosis 
and at survey compared to the non-compliers (without assessed hormones) and the compliers 
had significantly longer observation time [age at diagnosis: median 33 versus 31 years 
(P=0.006), age at survey: median 49 versus 45 years (P<0.001), observation time: median 15 
versus 13 years (P=0.028)]. No differences were observed between the compliers and non-
compliers in relation to lymphoma diagnosis and treatment groups. 
 Of the 294 compliers (n=165 HL survivors, n=129 NHL survivors), 64% (n=187) had 
received chemotherapy and radiotherapy, 21% (n=63) had had chemotherapy only and 15% 
(n=44) had received radiotherapy only.  
 In Paper 3 only males with assessed serum gonadal hormone levels were included in 
the study on sexual function. Three men reported current use of testosterone substitution 
therapy and were excluded, leaving 291 men in the sample. Of these, 246 had completed the 
Brief Sexual Function Inventory (BSFI) (120), which was used to assess sexual function.  
 Mean ages at diagnosis and at survey were significantly lower among those who had 
completed BSFI compared to those who had not completed the BSFI (n=45) (mean age at 
diagnosis: 32 years [SD = 9.4 years] versus 36 years [SD = 10.5 years] p=0.02; mean age at 
survey, 47 years [SD: =0.2 years] versus 51 years [SD =10.6 years], p=0.02). No significant 
differences were observed for follow-up time, proportion of HL versus NHL survivors or 
treatment group between the compliers and non-compliers of the BSFI. Seventy-nine percent 
of the male lymphoma survivors completing the BSFI were living in a committed 
relationship.  
 
Patients Paper 4 
 In 2001/2002 a cross-sectional survey including a questionnaire on various late effects 
and quality of life aspects after treatment was performed among consecutive HL survivors. 
The eligibility criteria for the study were: treatment period 1971 – 1998, age 18 – 75 years at 
time of survey, no relapse after 1998, no secondary cancer and a valid postal address. Since 
the study assessed attempted and achieved post-treatment parenthood females aged > 50 years 
and males aged > 65 years at survey were excluded. A total of 602 HL survivors were 
contacted by mail. For supplementary information on fertility, the female responders from 
2002 were contacted again in 2005, finally resulting in 269 male and 184 female responders.  
 There were no differences in observation time, initial stage, treatment group or relapse 
rates among responders and non-responders. In males, the responders were significantly older 
than the non-responders [29 versus 27 years (median)], whereas the opposite was observed in 
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females [26 versus 32 years (median)]. Eighty-six percent of the responders were aged < 40 
years at diagnosis, and 46% had at least one child at diagnosis. The median time from last 
treatment to survey was 15 years (range 3–34 years).  
 
Selection of control groups 
Control group Paper 1 
 Five controls per HL survivor were randomly drawn from the general population 
matched on the patient’s gender and year of birth (HL survivors, n=557, controls: n=2785).  
The draw was performed by Statistics Norway (SSB). The controls had to be alive on 
31.12.1993, as the HL patients were at the inclusion to the survey in 1994.   
 All subjects were followed from the survey in 1994 until date of death or to cut-off at 
January 1st 2007. The information on date of death and causes of death were retrieved from 
the Statistics for Causes of Deaths, Statistics Norway (SSB).  
  
Control group Paper 3 
 In 2004, a target population of 3500 men aged 20 - 79 years was identified using 
public address lists, and a questionnaire was mailed containing among other questionnaires 
the BSFI (121) to be completed and returned anonymously. The response rate was 34% (n = 
1185). For each lymphoma survivor participant two age-matched controls were drawn from 
this normative sample (lymphoma survivor participants n= 246, controls n = 492). 
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5.2.  Measures 
 
Questionnaires 
Sociodemographic Factors and Comorbidities (explanatory variables Paper3) 
 Men were classified as having a committed relationship if they were married or 
cohabiting versus those who were not. Level of education was dichotomized into 12 years 
versus >12 years of completed school years. Comorbidity was present if one of the following 
diseases were self-reported: myocardial infarction, angina pectoris, stroke, diabetes, asthma, 
or hypertension (defined by regular use of antihypertensive medication). Body mass index 
(BMI) defined as kg/m2 was also recorded. 
 
Brief Sexual Function Inventory (BSFI) (outcome variable Paper3) 
 Sexual function was assessed by the Brief Sexual Function Inventory (BSFI) which 
includes 11 items covering the following five sexual domains: sexual drive (two items), 
erectile function (three items), ejaculatory function (two items), problem assessment (three 
items), and overall satisfaction with sexual life (one item) (120;121). The response format 
ranges from 0 (poor function, big problem) to 4 (good function, no problem). The sexual 
domain scores were calculated by summing response scores of the individual items. Lower 
scores indicate poorer function. The BSFI domain scores were presented either as the sum 
score or as the average score per item. The BSFI total score was calculated by summing the 
scores of all items except the overall satisfaction item (BSFI items 1 to 10) as previously 
described  (121). Cronbach’s  measuring internal consistency of the BSFI total score was .93 
in the lymphoma survivor sample. 
To compare the prevalence of sexual problems among lymphoma survivors and 
controls, problems were defined as follows: drive problems: score  3, erection problems: 
score  7, and satisfaction problems: score  1, as described previously (122).  Because of 
some minor differences in wording between the BSFI administered to the lymphoma 
survivors and to the controls on the problem assessment and one of the ejaculatory items 
(BSFI items 7 to 10), the comparison between the lymphoma survivors and the controls was 
restricted to the other BSFI items.  
In Paper 3 sexual function was presented either as the BSFI total score or the mean 
score of each of the five sexual domains. 
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Fatigue Questionnaire (explanatory variable Paper1 and Paper3) 
 Fatigue was assessed by the Fatigue Questionnaire (FQ), which is a self-report 
questionnaire for assessment of fatigue severity and case detection in clinical and 
epidemiological studies (119). The FQ measures physical fatigue (7 items) and mental fatigue 
(4 items). The sum of all items is designated total fatigue. Two additional items ask about the 
duration and extent of fatigue. CF was defined by a sum score of  4 on the dichotomizes total 
fatigue score, which is indicative of clinically relevant levels of fatigue (119), and a fatigue 
duration of   6 months (41). Cronbach’s coefficient  was 0.90 for physical fatigue, 0.76 for 
mental fatigue, and 0.89 for total fatigue among the male lymphoma survivors (paper 3). 
 
Hospital Anxiety and Depression Scale (explanatory variable Paper3) 
 Levels of anxiety and depression were measured by The Hospital Anxiety and 
Depression Scale (HADS) which consists of 14 items, seven on the depression subscale and 
seven on the anxiety subscale (123;124). Each item is scored from 0 (minimally present) to 3 
(maximally present). The depression and anxiety scores were added to a total HADS score, 
with higher scores indicating more distress. The total HADS score was used as a continuous 
variable. Cronbach’s coefficient  was .89 for the total HADS score among the lymphoma 
survivors.  
 
Medical Outcomes Study Short Form 36 (explanatory variable Paper3) 
 The Medical Outcomes Study Short Form 36 (SF-36) is a self-reported measure for 
assessment of quality of life and includes eight dimensions (125;126). As previously reported, 
summary scores for physical health (Physical Component Scale [PCS]) and mental health 
(Mental Component Scale [MCS]) are derived by T-transformation (125) . Both scores have a 
mean of 50 and standard deviation of 10 points, and these figures are relevant for the 
Norwegian population (127). Both the PCS and the MCS were used as continuous variables in 
the analyses. Among the lymphoma survivors, Cronbach’s coefficient  was 0.82 for the PCS 
and 0.84 for the MCS. 
 
Gonadal hormone measurements (outcome variable Paper2 and explanatory variables 
Paper3) 
 Participating male lymphoma survivors had their blood samples drawn before noon by 
their general practitioners and they were mailed to the Department of Medical Biochemistry at 
Oslo University Hospital. Analyses of serum gonadal hormone levels (testosterone, sex 
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hormone–binding globulin [SHBG], luteinizing hormone (LH), and follicle-stimulating 
hormone [FSH]) were performed consecutively with the E170 module for Modular Analytics 
(Roche Diagnostic, Berlin, Germany).  
 Normal ranges for the gonadal hormones were: testosterone: 9.0 - 31.0 nmol/L; 
SHBG: 15 - 85 nmol/L; FSH: < 12.0 U/L; and LH< 10.0 U/L at the laboratory doing the 
analyses. The testosterone/SHBG ratio was calculated for each patient as a surrogate for free 
testosterone. 
 The patients’ gonadal hormone levels were categorized into three groups: 1: all 
gonadal hormones within the normal range; 2: elevated FSH but normal LH, SHBG, and 
testosterone (exocrine hypogonadism); and 3: low testosterone and/or elevated LH, 
independent of FSH (endocrine hypogonadism). This categorization was used to discriminate 
between patients with normal gonadal function, patients with damage only to the germinative 
epithelium (exocrine hypogonadism), and patients with Leydig cell dysfunction with or 
without damage to the germinative epithelium (endocrine hypogonadism). 
 
Grading of gonadotoxicity of treatment (explanatory variable Paper 2-4) 
 For the purpose of the studies on gonadal- and sexual function and post-treatment 
parenthood (Paper 2-4) the entire treatment (primary and relapse) for each patient was 
combined based on the records in the Lymphoma database of the NRH.  
 
Treatment groups paper 2 and 3  
 Since there is less knowledge concerning damage of the Leydig cell function by 
chemotherapy, the categorization of chemotherapy was performed according to the expected 
exocrine gonadal damage mainly based on the literature in low, medium and highly 
gonadotoxicity (37;42;83;104;128). In addition, in preliminary analyses, a separate group was 
constructed including patients who had received radiotherapy only. Analysis of this group 
showed no differences between patients who had received supradiaphragmatic radiotherapy 
only and those who had been irradiated with inverted Y / inguinal- or other 
infradiaphragmatic fields with respect to gonadal hormone levels. In addition, there was no 
difference between the group treated with radiotherapy only and the group treated with low 
gonadotoxic chemotherapy.   
 In Paper 2 the final treatment groups were defined as shown in Table 4. 
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Table 4. Grading of expected gonadotoxicity of chemotherapy in Paper 2. 
 
Expected 
gonadotoxicity 
 
Treatment 
 
 
No chemotherapy / low 
gonadotoxic chemotherapy 
Both HL and NHL 
No/low 
 
 
Radiotherapy only 
 
Rituximab only 
 
ABVP / EBVP and similar without regard to number of cycles 
 
 
Medium gonadotoxic 
chemotherapy NHL 
 
Med-NHL 
 
CHOP / COP / CHOEP  8 courses alone 
CHOP  8 courses combined with high dose Mtx 
 
MACOP B 
 
GMALL, BFM 90 
Hammersmith only 
Chlorambucil 
MIME 
 
 
Medium gonadotoxic 
chemotherapy HL 
 
Med-HL 
 
LVPP  4 courses alone or combined with ABOD / EBVP  
or dexa BEAM ( 2 courses) 
BEACOPP  4 courses 
OEPA + 0-4 COPP 
MIME 
 
 
Highly gonadotoxic 
chemotherapy NHL 
 
High-NHL 
 
CHOP > 8 courses 
CHOP = 8 courses combined with MIME, ENAP or Chlorambucil 
Maxi-CHOP  6 courses 
 
HDT with BEAM as conditioning regimen 
HDT with cyclophosphamide and TBI as conditioning regimen 
 
  
 
Highly gonadotoxic 
chemotherapy HL 
 
High-HL 
 
LVPP > 4 courses 
LVPP = 4 courses combined with CHOP or MIME 
BEACOPP > 4 courses 
 
HDT with BEAM as conditioning regimen 
HDT with cyclophosphamide and TBI as conditioning regimen 
 
HDT: high dose chemotherapy with autologous stem cell support. 
TBI : Total Body Irradiation. 
 
 In Paper 3 the five treatment groups from Paper 2 were merged into three groups:  
low: radiotherapy only and/or low gonadotoxic chemotherapy (both HL and NHL)  
medium: medium gonadotoxicity chemotherapy for NHL (“med-NHL”) and HL (“med-HL”)  
high: highly gonadotoxic chemotherapy for NHL (“high-NHL”) and HL (“high-HL”)  
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Treatment groups Paper 4 
 Chemotherapy was grouped according to expected gonadotoxicity of the regimens 
used in low, medium and highly gonadotoxic chemotherapy (37;42;83;104;128). 
In preliminary analyses no differences were observed between those irradiated with 
supradiaphragmatic radiotherapy only and those treated with infradiaphragmatic radiotherapy 
with or without supradiaphragmatic irradiation according to achieved post-treatment 
parenthood. Therefore, one treatment variable was constructed discriminating patients with 
radiotherapy only from those having chemotherapy with low, medium and highly 
gonadotoxicity (with or without radiotherapy) as shown in Table 5. 
 
Table 5. Treatment groups Paper 4. 
 
 
Treatment groups 
 
 
Radiotherapy 
only 
 
Chemotherapy 
with low 
gonadotoxicity 
 
 
Chemotherapy with 
medium 
gonadotoxicity 
 
 
Chemotherapy with 
high gonadotoxicity 
 
 
ABO(V)D 
 
ChlVPP  
 
ChlVPP  
EBVP MVPP MVPP 
 
 
Medium if  4 courses High if > 4 courses 
 
 CHOP 
MIME 
High dose 
chemotherapy with 
autologous stem cell 
support 
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5.3. Statistical considerations 
  
All papers 
 Data were analyzed using SPSS software versions 13.0 to 16.0. The level of 
significance was set at p<0.05 in all studies and all tests were two-sided. Means were 
compared by t-tests and categorical data were compared by x2 test. In case of skewed 
distributions, non-parametric tests were used. 
 
Paper 1 
 Observation time was calculated from January 1st 1994 until date of death or to cut-off 
at January 1st 2007 for both the HL survivors and controls. Crude cumulative probabilities of 
overall mortality were calculated for all subjects by the Kaplan-Meier method. Cox 
proportional hazard regression models stratified by the matched groups were used for 
univariate and multivariate analyses. Variables significant in the univariate analyses were 
entered into the multivariate Cox regression model. The proportionality of hazards 
assumption was investigated using log minus log plots. 
 Causes of deaths were categorized into three groups: 1: malignant tumor (all 
malignant diagnosis), 2: cardiovascular disease, 3: other (including infections, diabetes, 
pulmonal diseases, gastrointestinal diseases, diseases of the urinary system, diseases in the 
musculo-skeletal system, traumas and mental disorders). In case of death from tumors, these 
were further divided in two groups: 1: malignant lymphomas and 2: other malignancies, 
including solid tumors, multiple myeloma and leukemias. 
The risk of death was analyzed using a competing risk approach (129) with causes of  
death categorized in four groups: 1: malignant lymphomas, 2:other cancers, 3:cardiovascular 
diseases and 4: other causes of death. 
 
Paper 2 
 Multivariate analyses were performed as multinomial regression analyses with the 
dependent variable being the three groups of gonadal hormones: 1: normal (reference), 2: 
exocrine hypogonadism (elevated FSH, normal LH, testosterone and SHBG), 3: endocrine 
hypogonadism (low testosterone and/or elevated LH). The model was adjusted for the five 
treatment groups (1: No chemo/low gonadotoxicity, 2: medium gonadotoxicity NHL, 3: 
medium gonadotoxicity HL, 4: highly gonadotoxcicity NHL, 5: highly gonadotoxicity HL), 
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age groups and observation time. Preliminary analyses showed that time since diagnosis was 
not a significant factor associated with groups of gonadal dysfunction, and this variable was 
thus excluded from the final model.  
 
Paper 3 
 Univariate and multivariate linear regression analyses were performed with the BSFI 
total score as the dependent variable. Variables significant in univariate regression analyses 
were included as independent variables, and the strength of the associations was expressed as 
standardized beta-values. Statistically significant group differences were examined for clinical 
significance with effect sizes (ESs). For continuous variables we used Cohen’s coefficient d, 
and for 2 x 2 contingency tables the differences between arcsine transformed proportions and 
ES values  0.40 were considered as clinically significant based on the recommendations of 
Cohen (130;131). 
 
Paper 4 
 To discriminate for the introduction of ABVD chemotherapy, period of diagnosis was 
defined as 1: diagnosis before 1989 and 2: diagnosis in/after 1989. Factors influencing 
attempted post-treatment parenthood were analyzed by x2 tests for categorical variables, and 
by t-test for continuous variables. Binary logistic regression analyses were carried out with 
attempted post-treatment parenthood regarded as the dependent variable. 
 Evaluation of achieved post-treatment parenthood was restricted to patients who 
reported attempted post-treatment parenthood. Kaplan–Meier estimates, log-rank tests and 
Cox regression analyses evaluated the probability of achieved post-treatment parenthood, 
without use of assisted reproduction techniques, with the first post-treatment childbirth as the 
end point. Variables significant in univariate analyses were included as covariates in 
multivariate analyses together with the variables of major clinical interest (age, period of 
diagnosis, stage, treatment group).  
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6. Main findings 
Part I 
6.1. Main findings Paper 1   
Mortality in HL sample versus controls – all causes 
 By January1st 2007 death had occurred in 149 of the 557 HL survivors (27%) and in 
197 (7%) of the controls. Compared to the controls, HL survivors had nearly five times 
increased mortality (HR: 4.93 [95%CI: 3.91-6.21]). The ratio of mortality rate kept being 
positive for the entire observation period. Figure1a. 
 Among the three groups of HL survivors 72 deaths had occurred among participants 
without CF (22%), 35 deaths among participants with CF (31%) and 38 deaths among the 
non-participants (39%). When each patient group was compared to the matched control group 
the participants with CF had an increased mortality with HR: 4.85 (95%CI: 3.02-7.77), the 
participants without CF had an increased mortality with HR: 4.35 (95%CI: 3.16-6.00). 
However, for the non-participants the risk of mortality was more than 9 fold increased (HR: 
9.45 [95% CI: 5.44-16.41]) compared to their controls.  
Variables significantly associated with mortality among the HL survivors 
 The participants with CF (HR: 1.54, 95%CI: 1.03-2.31) and the non-participants (HR: 
2.04, 95%CI: 1.37-3.02) had increased mortality compared to the participants without CF in 
univariate analyses. Figure1b.  
 Multivariate analysis showed that the non-participants had a two-fold increased risk of 
mortality (HR: 2.05, 95%CI: 1.37-3.07) compared to participants without CF. No statistically 
significant difference was observed between the participants with and without CF. About 
three times higher mortality was observed in HL survivors treated with radiotherapy (with or 
without chemotherapy) compared to those treated with chemotherapy only in the multivariate 
analyses. HL survivors diagnosed before 1981 had increased mortality compared to those 
diagnosed in 1981 or thereafter. 
Causes of deaths 
  Among the HL survivors 83 of the 149 (56%) deaths were caused by malignant 
diseases and 36 (24%) were caused by cardiovascular diseases. Of the HL survivors who died 
of malignant diseases, 33 of these deaths were caused by malignant lymphomas (of which 21 
by HL) and 50 by other cancer types (pulmonary cancer: n=20, cancer in the gastrointestinal 
tract: n=11, breast cancer: n=3, leukemias / multiple myeloma: n=3).  
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 Compared to the controls, the HL survivors had more than six times increased 
mortality of cancer (HR: 6.6, 95%CI 4.7-9.2), and almost five times increased mortality of 
cardiovascular disease (HR: 4.9, 95%CI: 3.1-7.9). 
 
 
Figure1. 
 
a. 
 
b.  
 
   
Figure1a : Cumulative overall mortality rate in HL sample (HL: n = 557) and controls (Ctrs: n = 2785) 
Figure1b :  
Cumulative mortality rate in HL survivors related to patient group and the matched control groups.  
All patient groups displayed increased mortality compared to their controls (p<0.001). 
HLSs:  I: Participants without chronic fatigue (CF) n = 329 
II: Participants with CF, n = 113 
III: Non participants, n = 98 
Ctrs: controls 
  CtrsI: controls to participants without CF, n = 1645 
 CtrsII: controls to participants with CF, n = 565 
 CtrsIII: controls to non-participants, n = 490 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ctrs 
HL 
III 
II 
I 
Ctrs II,I, III  (from above) 
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Part II  A 
6.2. Main findings Paper 2 
Levels of FSH, LH, Testosterone and SHBG 
 Forty-one percent of the male lymphoma survivors had FSH values above normal 
level (>12.0 U/L) and 16% of the survivors had elevated LH (>10.0U/L). The median 
testosterone value was 12.9 nmol/L (range: 1.7–33.9 nmol/L), with 20% of the survivors 
having testosterone value below the normal level (<9.0 nmol/L).  
 There was a significant association between age at survey and the levels of FSH, LH 
and SHBG (p<0.001), with levels increasing by age. For testosterone, no significant 
association with age at survey was observed. Figure 2a. 
 
Figure 2a. Levels of gonadal hormones related to age groups. 
a.FSH
 
b.LH 
 
c.SHBG
 
d.Testosterone
 
Age groups: 1: 21-39, 2: 40-49, 3: 50-56, 4: 57-75 years at survey. 
Boxplot showing median, upper and lower quartiles and range of values. 
Datas from table 4 in Paper 2 presented as boxplot 
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Figure 2b. Levels of gonadal hormones related to treatment groups. 
a. FSH 
 
b. LH 
 
c. SHBG 
 
d. Testosterone 
 
Treatment groups:  
1: radiotherapy only / low gonadotoxic chemotherapy,  
2: medium gonadotoxic chemotherapy NHL,  
3: Medium gonadotoxic chemotherapy HL,  
4: highly gonadotoxic chemotherapy NHL,  
5: Highly gonadotoxic chemotherapy HL. 
See table3 page 31 for explanation of treatment groups. 
Data from table 4 in Paper 2 presented as Boxplot showing median, upper and lower quartiles and range of 
values. 
  
 There was a significant association between the levels of both FSH, LH (p<0.001) and 
SHBG (p=0.042) and treatment groups. The median level of FSH and LH increased 
significantly in all other treatment groups compared with patients treated with no/low 
gonadotoxic chemotherapy (p<0.001 – p<0.02). For testosterone no association with 
treatment groups was found, Figure 2b. 
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Groups of gonadal dysfunction 
 About half of the male lymphoma survivors (n=144, 49%) had all gonadal hormones 
within normal ranges and 20% (n=60) had isolated elevated FSH, with LH, SHBG and 
testosterone within normal ranges. Almost one-third of the survivors (n=90, 31%) had 
testosterone below and/or LH above normal range. There was a statistically significant 
association between treatment group and groups of gonadal dysfunction (p<0.001). Seventy-
nine percent of those treated with no/low gonadotoxic chemotherapy had normal gonadal 
hormones, whereas the comparable figures were 62% after med-NHL, 26% after med-HL, 
16% after high-NHL and 8% after high-HL. Figure 2c. 
Figure 2c. 
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Legends Figure 2c. (same as figure 1 in paper 2) 
Proportions of normal gonadal hormones, exocrine hypogonadism (elevated FSH, normal LH, 
testosterone and SHBG) and endocrine hypogonadism (low testosterone and/or elevated LH) in 294 male 
lymphoma survivors related to treatment group. 
Treatment groups:  
No chemo/low: radiotherapy only and low gonadotoxic chemotherapy (n=99) 
Med-NHL: medium gonadotoxic chemotherapy for NHL (n=73) 
Med-HL: medium gonadotoxic chemotherapy for HL (n=43) 
High-NHL: highly gonadotoxic chemotherapy for NHL (n=43) 
High-HL: highly gonadotoxic chemotherapy for HL (n=36) 
For definitions of treatment groups, see table3 page 33. 
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Multinomial regression analyses 
 Compared to those treated with no/low gonadotoxic chemotherapy patients from all 
the other treatment groups had significantly elevated odds ratios (OR) for exocrine 
hypogonadism (elevated FSH only). Patients in the med-NHL group were 6.3 (95% CI: 1.7–
23.8) times more likely to have elevated FSH compared to those treated with no/low 
gonadotoxic chemotherapy. The comparable ORs for the other groups were 25.7 (95% CI: 
6.2–107.0) after med-HL, 73.3 (95% CI: 17.2–312.2) after high-NHL and 112.0 (95% CI: 
20.1–625.2) after high-HL. Age at survey was not significantly associated with exocrine 
hypogonadism. 
 Except for those in the med-NHL group, patients from the other treatment groups had 
significantly elevated risk also for endocrine hypogonadism (low testosterone and/or elevated 
LH) compared to the group treated with no/low gonadotoxic chemotherapy. Patients in the 
med-HL showed OR=8.0 (95% CI: 3.2–20.4) for having endocrine hypogonadism compared 
to those treated with no/low gonadotoxic chemotherapy, whereas the comparable ORs for 
high- NHL were 10.5 (95% CI: 3.6–30.6) and 37.2 (95% CI: 9.4–147.7) for high-HL. 
 Patients aged above 50 years at survey were about five times more likely to have 
endocrine hypogonadism compared to those younger than 40 years at survey. 
OR with 95%CI from table 5 in Paper 2. 
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6.3. Main findings Paper 3 
Sexual Function: HL versus NHL survivors  
 When adjusted for age, initial stage, and intensity of chemotherapy, there was no 
significant difference between HL and NHL survivors concerning the BSFI domain and total 
scores. Therefore, the whole lymphoma group taken together was compared with the controls.  
Sexual function in lymphoma survivors versus normative controls 
 The lymphoma survivors had significantly poorer sexual function than normative 
controls in the BSFI erection, ejaculation, and overall sexual satisfaction domains (p 0.02 for 
all) after adjusting for relationship status Figure 3a. There was no significant difference 
observed in the drive domain. The effect sizes were modest, ranging from 0.17 to 0.26.  
 
Figure 3a. Sexual function in male lymphoma survivors compared to age-matched 
controls (figures from table 5 Paper 3). 
 
 
 
 
 
 
Factors associated with reduced sexual function among the lymphoma survivors 
  All five BSFI domains and the BSFI total scores decreased with increasing age 
(p0.002 for all) Figure 3b. Lymphoma survivors with normal gonadal hormone levels had 
the best sexual function scores, whereas the poorest scores were found in the survivors with 
low testosterone and/or elevated LH (p<0.05) Figure 3c. 
 In multivariate analyses older age (p<0.001), more emotional distress (total HADS 
score; p<0.001), and poorer physical health (PCS; p=0.03) were significantly associated with 
poorer sexual function (BSFI total score). Compared with having normal gonadal hormones, 
having low testosterone and/or elevated LH was also associated with poorer sexual function 
(p=0 .04). 
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Figure 3b. BSFI total score related to increasing age in male lymphoma survivors and 
controls 
 
        
Age goups: 1:21-39 years, 2: 40-49 years, 3:50-59 years, 4: 60-69 years at survey. 
 
 
Figure 3c. BSFI total score related to groups of gonadal hormones in male lymphoma 
survivors (figure from table 4 paper 3). 
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Part II  B 
6.4. Main findings Paper 4 
Attempted post-treatment parenthood 
 Attempted post-treatment parenthood was reported by 92 (50%) female and 120 
(45%) male HL survivors, all aged below 40 years at diagnosis. Younger age and 
childlessness at diagnosis were the only variables significantly associated with attempted 
post-treatment parenthood in both univariate and multivariate analyses.  
 
Achieved post-treatment parenthood 
 The 10-year cumulative probability of post-treatment parenthood was 59% in females 
and 56% in males with no significant difference between genders Figure 4a.  
 Females younger than 30 years at diagnosis had significantly higher probability of 
getting children post-treatment compared to older females. In males, there were no significant 
differences between the age groups Figure 4b. 
 Male HL survivors had a significantly higher probability of post-treatment fatherhood 
after radiotherapy only and after chemotherapy of low gonadotoxicity compared to those 
treated with chemotherapy with medium or high gonadotoxicity. The 10-year cumulative 
probabilities of achieving post-treatment parenthood in the various treatment groups were: 
71% after radiotherapy only, 85% after chemotherapy with low gonadotoxicity, 35% after 
chemotherapy with medium gonadotoxicity and 18% after chemotherapy with high 
gonadotoxicity Figure 4c. 
 A significantly higher probability of getting children post-treatment was observed 
after radiotherapy only compared to chemotherapy with either medium or high gonadotoxicity 
also in females. A significant difference was also seen between those treated with 
chemotherapy with low versus high gonadotoxicity. The 10-year cumulative probabilities of 
post-treatment motherhood were 82% after radiotherapy only, 55% after low gonadotoxic 
chemotherapy, 51 % after medium gonadotoxic chemotherapy and 27% after highly 
gonadotoxic chemotherapy Figure 4d. 
 In the multivariate analysis post-treatment parenthood was significantly associated 
with treatment groups in both males and females. In males, the period of diagnosis was also a 
significant factor. 
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 In addition, thirteen men had used assisted reproduction techniques with pretreatment 
cryopreserved semen, 10 of them successfully becoming fathers. Two women reported to 
have used IVF/ICSI, one of them giving birth to one child. 
  Finally, at the end of the observation time, 69 (76%) of the females and 85 (71%) of 
the males who had attempted post-treatment parenthood had become biological parents. 
 
Figure 4 (parts similar to figure 2 in Paper 4) 
 
 
 
 
 
4a. 
4c.
4b. 
4d. 
 48
7.  Discussion 
 
7.1. Methodological considerations 
Response rates  
High response rates among survivors after treatment for HL and NHL represent one of 
the strengths of this survey. For the questionnaire surveys in 1994 and 2002 (Paper 1 and 4) 
response rates of 82% and 75% were obtained, which is considered highly satisfactory for 
such studies. 
For the study on gonadal hormones in 2007 (Paper 2 and 3) a response rate of 45% 
was achieved for the assessment of serum gonadal hormones, which is lower than what is 
generally obtained in questionnaire-based surveys, but should be viewed on the background 
of collection of blood samples and completion of a questionnaire. In addition, only male 
patients were included in the survey, with generally lower compliance on questionnaire 
studies than females. Nevertheless, serum samples from 294 male survivors could be analyzed 
by a single laboratory, and 246 of these survivors completed the BSFI (Paper 3). Compared to 
the existing literature in this field, this is a large sample size, not at least as the 2007 survey 
assessed sexual function since this theme often further reduces the response rates (121). 
Reluctance to complete the intimate questions of the BSFI is also the most probable 
explanation for the relative low response rate of this questionnaire among males from the 
general population.  
 
Cross sectional studies 
 In cross-sectional studies, information is collected at one point in time. Therefore, 
cross-sectional studies are suited for measuring prevalence rates and detecting associations 
between variables. However, significant differences or associations observed do not prove 
causal relationships.  
 The cross-sectional design was considered appropriate for the objectives in Paper 2-4 
because we were interested in assessing prevalence of gonadal dysfunction with associations 
to treatment and age in Paper2,  the associations of reduced sexual function in male 
lymphoma survivors in Paper 3, and the rates of attempted and achieved post-treatment 
parenthood in Paper 4.  A prospective design would probably give more information on the 
natural course of the late effects studied in these papers with improved knowledge of 
variations over time, but would require more time and labor to accomplish. 
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Time to event 
 In Paper 1 the endpoint for the survival analyses was date of death for HL survivors 
and controls with sensoring 13 years after the 1994-survey. This information was retrieved 
from the Statistics Norway (SSB), which are considered to provide accurately information. 
 In Paper 4 the endpoint for the survival analyses was year of the first post-treatment 
childbirth without considering abortions. This information was provided from the 
questionnaires, and it was expected that parents gave the correct year of birth for their 
children. 
  
Bias  
Bias can be categorized in three groups: selection bias, confounding and information bias. 
 Selection bias results from procedures used to select subjects of the study population, 
and selection bias occurs when the association between the exposure and the outcome differs 
systematically between those who participated and those who did not within a sample. 
 Paper 1 demonstrates that the characterization of non-response represent a significant 
problem in questionnaire based surveys. Our result indicate that significant differences 
between responders and non-responders remained undetected in 1994, in spite of 
comparability on important medical and sociodemographic parameters. As far as we know, a 
significant association between the willingness / ability to respond to a questionnaire survey 
and increased mortality has not been previously described in cancer survivors. This finding 
indicates that impaired physical health may explain why some HL survivors did not respond 
to the survey in 1994. A possible higher burden in non-responders as to having more 
symptoms and impaired physical health may imply that adverse effects in HL survivors might 
be underestimated in follow-up surveys due to selection bias.  
In addition, the cross-sectional nature of the 1994-survey makes our result biased 
toward to higher rate of survival compared to other studies on mortality in HL survivors, since 
only HL survivors alive in 1994 were included in our sample.  
 In Paper 2 the compliers (with assessed serum gonadal hormones) were older at 
survey than the non-compliers (without assessed serum gonadal hormones). This may have 
caused a biased sample with a higher proportion of lymphoma survivors having endocrine 
hypogonadism (low testosterone and/or elevated LH) in our patient sample than in the total 
sample since the testosterone levels decrease with increasing age in the general population 
(132).   
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 In Paper 3 those who had completed the BSFI (n=246) were younger at diagnosis and 
at survey compared to those who had not completed BSFI (n=45), which may give bias 
towards better sexual function in the responders than in the total sample of male lymphoma 
survivors approached. This may indicate that the extent of reduced sexual function in the total 
sample approached might be higher than suggested by our results since sexual function 
decreases with increasing age in the general population.  
 In Paper 4 we related our end point, achieved post-treatment parenthood, to the 
number of patients who reported attempted post-treatment parenthood. However, the number 
of HL survivors who reported to have attempted post-treatment parenthood may represent a 
response bias because only surviving patients could report their attempts of post-treatment 
parenthood. This could lead to an underestimation of attempts on post-treatment parenthood. 
Reported rates of parenthood after treatment for cancer will depend on the selection 
criteria of the samples. In our study sample, 68% of those who reported to have attempted 
post-treatment parenthood conceived children spontaneously. As the proportion of patients 
who reported to have attempted parenthood may be underestimated, our reproduction rates 
may therefore be too favorable.  This point is supported by the findings from a registry-based 
study from our group, showing a 20-year probability of first post-treatment childbirth of 8% 
in female and 28% in male lymphoma patients aged 15–45 years at diagnosis, when all 
patients treated at the NRH are included in the denominator without consideration of 
attempted post-treatment parenthood (133).  
Confounding factors are variables in statistical models that correlate (positively and 
negatively) with both the dependent variable and the independent variable. Failure to control 
for such factors influencing the outcome may lead to confounding bias. In the studies 
included in this thesis, we have tried to avoid such bias as much as possible by adjusting for 
potential confounders in the analyses. 
As an example, in Paper 1, the univariate analysis showed that participants with CF 
had significantly increased mortality compared to participants without CF. The significance of 
this difference disappeared in the multivariate analysis, probably reflecting confounding by 
age, since the chronically fatigued HL survivors were significantly older than those without 
CF in 1994. However, not all potentially confounders are known about this patient sample and 
could therefore not be adjusted for, like for instance comorbidity present in 1994. 
 In paper 3 a higher proportion of the controls from the general population lived in a 
committed relationship compared to the lymphoma survivor sample, and since relationship 
status is associated with sexuality, this was adjusted for when analyzing differences in the 
 51
BSFI in order to get the effect of the treatment of the disease teased out from that of the 
relationship status.  
  
Internal validity 
 Internal validity refers to which extent the results of the studies can be generalized to 
the whole sample of lymphoma survivors approached in the surveys included in this thesis. In 
order to estimate the internal validity representativeness, possible biases and confounding 
factors which may affect internal validity have to be considered (134). In cross-sectional 
questionnaire-based surveys, there will always be some differences between the responders 
and the non-responders. Accounting for the limitations of the various differences between the 
reponders and non-responders in the samples of lymphoma survivors approached, as 
mentioned above, and the adjustment for confounding factors, we overall consider the internal 
validity of the surveys included in this thesis to be as good as possible. 
  
External validity   
 External validity refers to the extent a study’s results can be generalized to other 
populations than the study population, and for the present study this means to which degree 
our results can be generalized to the Norwegian lymphoma survivors in general.  
 In the period 1970-1980 the treatment of HL in Norway was centralized to the NRH, 
and 92% of the patients aged 15-39 years and 80% of the patients aged 40-59 years were 
admitted to the hospital. Since 1981 four other national oncological centers gradually began to 
treat HL following the same treatment principles as the NRH (49). From 1985 all HL patients 
from a defined health region constituting about 50% of the Norwegian population have been 
referred to the hospital. The treatment of HL at the NRH has been performed according to 
national and international guidelines. On this background we consider the external validity for 
the results on the HL patients included in this thesis to be very good and that our results may 
be generalized to the Norwegian HL survivors in general. 
 The proportion of NHL patients referred to the NRH has been somewhat lower than 
the proportion of HL patients, but the treatment of NHL has been performed according to 
national guidelines. With this background we consider the external validity of our results to 
be good and that our findings also can be transferable to the Norwegian population of male 
NHL survivors for the age groups examined in our analyses. 
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The use of normative controls 
 The use of control groups drawn from the general population allows comparison of the 
findings in the lymphoma survivors to that of the general population. This is of importance 
because health problems in cancer survivors may also be prevalent in the general population.  
 For Paper 1, a control group was constructed by randomly drawing five controls per 
patient from the general population matched for gender and year of birth, and these controls 
were followed similarly as the HL survivors. The use of matched controls gave the 
background mortality rate of the general population in order to evaluate the mortality rate in 
the HL survivors. Moreover, having five controls per patient compensated for random error in 
population sample controls. 
 In Paper 3 two age-matched controls were drawn from the normative sample (121) for 
each lymphoma survivor participant. This allowed us to compare sexual function in male 
lymphoma survivors compared to age matched controls, data which have been lacking in the 
literature so far. However, the information about the controls is limited by the lack of 
hormonal and other health data from men in the comparison group. The relatively low 
response rate (34%) in the normative sample also seen in other questionnaire studies of sexual 
function is another limitation because we do not know the representativity of the sample in 
relation to the total population. 
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7.2. Discussion of specific results 
Part I 
Mortality and causes of deaths in HL survivors compared to matched controls (Paper 1) 
 This study provides information on long-term mortality and causes of death in HL 
survivors with a longer follow-up period than previous studies (31;43;44). The median 
follow-up time was 12 years from diagnosis to the survey in 1994, and this study prolonged 
the observation time until 2007.  
 Compared to the controls, the HL survivors had almost five times higher risk of death 
due to any cause, and the mortality of HL survivors was persistently higher than the rate of 
their controls throughout the entire observation period. The presence of CF was not 
significantly associated with increased mortality, which is of clinical importance, as it 
indicates that CF itself is not associated with life-threatening somatic morbidity. 
Unexpectedly, an increased mortality among the non-participants from the 1994-suvey was 
observed.  
 At inclusion in the 1994-survey, the HL survivors were considered to be in complete 
remission. However, the observation time from diagnosis to inclusion in 1994 had a wide time 
span ranging from 2 – 23 years, with those with the shortest observation time from diagnosis 
to the 1994-survey having the highest risk for relapse.  
 Patients diagnosed in the period 1971 – 1980 had increased mortality compared to 
those diagnosed in the period 1981 – 1991, which is comparable to earlier findings (43). The 
difference in mortality over time periods may be due to more toxic treatment in the first 
period, particularly caused by the use of larger radiation fields, whereas less toxic treatment 
options were available in the latter period. Another explanation is change in the 
histopathological diagnosis; some lymphomas classified as HL in the earliest period, 
especially of the lymphocyte depleted and unclassified subtypes in the elderly (considered to 
be associated with poor prognosis), probably have been classified as NHL during the second 
period (49). 
 Malignant diseases and cardiovascular disorders were the most frequent causes of 
deaths among the HL survivors, which is similar to previous reports (28;31). Mortality of 
cancer was more than six times higher in HL survivors compared to the control group, and 
almost five times higher for mortality due to cardiovascular disorders. These results are 
comparable to those observed in 1261 patients treated for HL before the age 41 where the 
relative risk (RR) of deaths resulting from solid tumors was 6.6 and for cardiovascular 
diseases 6.3 (28). In comparison, Ng et al reported the RR of excess mortality from second 
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tumors to be 11.2 and 3.2 from cardiovascular diseases in their cohort of 1080 HL survivors 
(31).  
 Over the last decades, treatment for HL has been modified in order to reduce long-
term adverse effects without changing the very good survival rates. Extended radiation fields, 
such as Mantle and inverted-Y field, is no longer used as standard radiotherapy, and for 
chemotherapy, MOPP-like regimens have to a large extent been abandoned. Nevertheless, it 
is of importance to study the morbidity and mortality after treatment with these regimens 
because a large number of survivors after such treatment are still alive, and for these is it of 
importance that medical complications can be prevented if possible, detected and eventually 
treated. In addition, today’s patients still receive radiotherapy, albeit to smaller volumes and 
with lower doses, and chemotherapy regimens used today, such as ABVD and BEACOPP, 
still contain many of the same compounds as did earlier regimens. In a recently published 
study comparing overall survival (OS) after treatment for advanced stage HL with  
COPP/ABVD, BEACOPP or escalated-dose BEACOPP (median follow-up 111 months), OS 
was reported to be significantly improved after treatment with escalated-dose BEACOPP 
compared to the two other treatment regimens (135). However, a higher number of acute 
myeloid leukemia and myelodysplastic syndrome was observed in the dose-escalated 
BEACOPP arm, whereas no differences were observed in the total number of secondary 
malignancies between the treatment arms (135). This report emphasizes the importance of 
clinicians being aware of the possibility of long-term complications even after today’s 
treatment for HL, warranting optimal follow-up care of the patients. A question is whether the 
total long-term mortality is a better estimate of successful treatment of HL, than HL specific 
mortality. 
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Part II A 
Gonadal function in male lymphoma survivors (Paper 2) 
 Almost 50% of the 294 male lymphoma survivors had all gonadal hormones within 
normal ranges, 20% had isolated elevated FSH (exocrine hypogonadism), and almost one-
third had low testosterone and/or elevated LH (endocrine hypogonadism). Patients from all 
the other treatment groups had significantly elevated risk for having elevated FSH compared 
to those treated with radiotherapy only / chemotherapy with low gonadotoxicity. Except for 
the patients in the med-NHL group, patients from the other treatment groups had a 
significantly elevated risk also for endocrine hypogonadism compared to the group treated 
with radiotherapy only / chemotherapy with low gonadotoxicity. Patients aged above 50 years 
at survey were about five times more likely to have endocrine hypogonadism compared to 
those younger than 40 years at survey. 
 In the present lymphoma sample, 41% had elevated FSH, which is comparable to 35% 
reported after at a median follow-up of 32 months after treatment for stage I/II 
supradiaphragmatic HL in the period of 1982 to 2004 (n=355) (85). However, this has to be 
considered in the light of major differences between the two patient samples. Our sample 
included survivors after both HL and NHL, men with initially advanced disease and treated 
for relapse, and thereby those who had received more intensive chemotherapy than usually 
given in stage I/II disease. Finally, our median observation time was 15 years and thereby 
much longer than that of van der Kaaij et al (85). We consider our proportion of FSH 
elevation as definite, whereas one still can expect some recovery of spermatogenesis with 
longer follow up in early stage lymphoma patients with limited treatment, based on the 
experience in testicular cancer patients (136). 
 The results of our study supported findings of low risk of elevated FSH in HL 
survivors after treatment with ABVD-like regimens or radiotherapy only compared to 
chemotherapy combinations incorporating alkylating agents (42;85;90). A recent report on 
fertility in males treated for advanced stage HL with BEACOPP regimens (n=38) showed that 
the majority of patients had elevated FSH levels and were azoospermic after treatment (137). 
  The risk of elevated FSH increased with chemotherapy intensity also in male 
survivors after treatment for NHL. To our knowledge, this has not been shown in such a large 
patient sample earlier, but is comparable to the findings of Pryzant et al showing that 
cumulative doses of cyclophosphamide higher than 9.5 g/m2  resulted in significanlty lower 
probability of recovered spermatogenesis compared to cumulative doses of cyclophosphamide 
less than 9.5 g/m2 (86).  
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 Except for male NHL survivors treated mainly with CHOP-based chemotherapy (med-
NHL group), the risk of endocrine hypogonadism (low testosterone and/or elevated LH) 
increased for all treatment groups compared to the group treated with radiotherapy only or 
low gonadoxic chemotherapy. Intensification of chemotherapy increased the risk of endocrine 
gonadal failure more in HL survivors than in NHL survivors. This result may reflect that 
chemotherapy regimens used for HL generally are more gonadotoxic than those used for 
NHL. This difference may also be explained by the differences in the pre-treatment gonadal 
function between HL and NHL patients as previously reported (80). Also for testicular cancer 
survivors an increasing risk of endocrine hypogonadism along with chemotherapy 
intensification has been reported (138). 
 We have followed the definition of endocrine hypogonadism based on elevated LH 
and normal testosterone (compensated hypogonadism) or low testosterone with or without 
elevated LH (40). Our data indicated that the duration of follow-up time might be associated 
with development of an uncompensated hypogonadism (elevated LH, low testosterone). In 
addition, our patient sample showed a more diverse picture regarding the endocrine 
dysfunction, with 27 of 57 patients with low testosterone having normal LH. Similar results 
has been reported earlier by Greeenfield et al, with only one third (8/24) of male cancer 
survivors with low testosterone value having elevated LH (75). This finding may reflect that 
the causes of endocrine hypogonadism in male lymphoma survivors may be more complex 
than previously described. Chemotherapy and/or radiation-induced damage may develop 
either in the gonads, the hypothalamus-pituitary axis or as a combination of these two. 
Further, except for the pathway through the hypothalamus–pituitary axis and the release of 
Gonadothropin-releasing hormone (GnRH), the mechanisms related to Leydig cell 
dysfunctions after cancer treatment are not well known. In addition, it has been noted that 
lower testosterone levels in elderly males may not be fully accompanied by rising FSH and 
LH levels (139). 
 The blood samples for assessment of the gonadal hormones were generally taken 
during the morning, since testosterone levels have a diurnal variation with highest levels in 
the mornings. The normal range for serum levels of testosterone (9-31 nmol/l) was not age 
adjusted in the laboratory at the NRH which analyzed all the gonadal hormones, which may 
have lead to a comparatively broad allocation of older men to the group of endocrine 
hypogonadism. However, a recent report on reference intervals for serum testosterone, 
SHBG, FSH and LH, with analyses performed at the same laboratory as our samples, the 
normal range for age 70 years was 8.6-30.7 nmol/l which is quite similar to the normal range 
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used in the present study (139). For the age group 40-50 the normal range for testosterone was 
found to be 9.7-31.8 nmol/l (139), which in retrospect indicates that our estimates of 
endocrine hypogonadism in the younger male lymphoma survivors have been an 
underestimation. 
 Testosterone deficiency in adult males has been associated with negative health effects 
such as declining bone mass, increasing BMI, reduced muscle strength and energy levels in 
addition to altered sexual function both in cancer survivors and in the general population 
(75;76;140;141). It is therefore of clinical importance to identify male cancer survivors with 
endocrine hypogonadism, and in this context, it is surprising that only three of the male 
patients included in this study reported testosterone substitution therapy at the time of the 
survey, when endocrine hypogonadism was found in one-third of the patients. This is 
probably because levels of gonadal hormones have not been measured regurlarly in male 
lymphoma survivors.  
    
Sexual function in male lymphoma survivors (Paper 3) 
 Lymphoma survivors reported statistically significant poorer sexual function in the 
domains of erection, ejaculation, and overall sexual satisfaction compared with age-matched 
controls. Among the lymphoma survivors the most important variables associated with 
reduced sexual function were older age, more emotional distress and poorer self-reported 
physical health. Lymphoma survivors having low testosterone and/or elevated LH displayed 
impaired sexual function compared to those with normal gonadal hormones.  
The gradual reduction of sexual function with increasing age in the lymphoma sample 
is similar to reports from the general population (98;121). A previous survey of male 
lymphoma survivors did not find an association between age and reduced erectile function, 
but only men under age 55 were studied and the sample size (n=59) was much smaller than 
ours (96), which may explain the differerences between their findings and ours. 
 The finding of an association between sexual function and Leydig cell or pituitary 
dysfunction in our study is similar to the results of studies of men from the general population 
and observations from a group of men treated for hematological malignancies (132;142-144). 
However, in both the study by Howell et al (144) and our sample, the hormonal abnormalities 
only accounted for a small part of the decline in sexual function. In the multivariate analysis, 
emotional distress and report of poor physical health remained associated with reduced sexual 
function at a much higher degree, which is similar to findings in studies of testicular cancer 
survivors (122) and in aging men in the general population (95;97). The association between 
low testosterone levels and reduced sexual function may be explained in different ways. First, 
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low testosterone levels may directly decrease physical health and impair sexual function as a 
consequence of the gonadal dysfunction. Second, systemic illness may result in reduced 
testosterone levels and may direct impact on sexual function. 
It is generally assumed that if a man’s testosterone levels are below the normal range, 
testosterone supplementation will improve sexual function. However, it is difficult to assess 
the effects of testosterone substitution on sexual function because most studies are 
methodologically flawed (143;145). A conservative approach would be to treat cancer 
survivors with sexual dysfunction initially by encouraging a healthy lifestyle, particularly in 
terms of increasing physical exercise and eventual weight reduction (143;145). Such an 
approach may improve hypertension, diabetic control, and other cardiac risk factors. Men 
who might not be motivated to make lifestyle changes to prevent future health problems 
might be receptive to such a program if it could improve sexual function. 
 Although impaired sexual function may be a distressing late effect for men after 
lymphoma treatment, many do not receive information about the impact of cancer treatment 
on sexuality. In a survey assessing information needs in survivors of NHL, 28% wanted 
information about sexual functioning (91). Sexual counseling is not routinely available even 
in comprehensive cancer centers in the United States (146). A survey from a large cancer 
center reported that 51% of responding male cancer survivors stated that they most probably 
would make an appointment at a reproductive health clinic in the next year if the cancer 
center offered such a service (147).  
 
Part II B 
Post-treatment parenthood in HL survivors (Paper 4) 
 Approximately half of the HL survivors reported attempted post-treatment parenthood, 
and among these, two thirds (68 %) were successful in becoming parents without use of 
assisted reproduction techniques. Multivariate analyses revealed that type of treatment was 
significantly associated with post-treatment parenthood in both genders, with highest 
probabilities after radiotherapy only and low gonadotoxic chemotherapy. In addition, a 
significantly higher success rate was observed in males diagnosed after 1988 compared to 
before 1989. 
 Most studies on post-treatment gonadal function in HL survivors have assessed 
secondary amenorrhea and /or spermatogenesis measured by sperm cell count and the level of 
serum FSH (37;42;89;99). For females, regular menstruation post-treatment does not equal 
ovulation and the possibility of pregnancy. For males, however, sperm count analyses and 
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serum levels of FSH are relatively valid indicators of fertility. Some studies on fertility in HL 
survivors have reported the number of childbirths, but often in small series (100-103), and 
rarely with those attempting post-treatment parenthood as a denominator (36;104). 
 Achievement of post-treatment parenthood was associated with treatment groups in 
both males and females. Our results correspond to earlier reports on male fertility after 
treatment for HL, with higher rates of preserved fertility after treatment with ABVD-like 
regimens compared to MOPP-like regimens (42;89;99;100). In our patient sample, two male 
patients spontaneously fathered children after HDT. Earlier studies have reported that fertility 
may be restored in a few patients after treatment with HDT for HL and NHL (148;149). Only 
a small proportion of the male HL survivors had used their pretreatment cryopreserved semen, 
which has also been shown for other cancer survivors (106;107). 
 The improved chance of post-treatment parenthood in males diagnosed after 1989 
compared to before 1989 is probably due to changes in the treatment of HL in late 1980s with 
introduction less gonadotoxic chemotherapy, such as ABVD, and less extensive radiation 
fields. In the females, our findings support earlier studies which have shown that female post-
treatment fertility depends both on the gonadotoxicity of chemotherapy and age at diagnosis 
(37;101-104).  
 In preliminary analyses no differences were found in post-treatment parenthood after 
supradiaphragmatic radiotherapy only compared to infradiaphragmatic irradiation. However, 
the majority of the irradiated patients had received supradiaphragmatic radiotherapy only 
(almost 80%), and the group of HL survivors who had attempted post-treatment parenthood 
after infradiaphragmatic radiotherapy was too small for valid statistical comparison. As earlier 
reported, successful pregnancies are possible after pelvic irradiation if oophoropexy has been 
performed before inverted-Y field irradiation (150) or the radiation field did not include both 
ovaries. 
 This study has some limitations: neither the fertility status of the HL survivors’ 
partners is known, nor the couples struggle for achieving children, with the exception of the 
use of assisted reproductive techniques. Concerning reports of attempted post-treatment 
parenthood, there may be some degree of memory bias of the patients. In addition, a response 
shift from “have attempted” to “have not attempted” post-treatment parenthood as part of a 
coping strategy in some patients that did not succeed in having children post-treatment can 
not be excluded. It is also unknown to us at what time after treatment the HL survivors started 
attempting parenthood. In addition, we assume that male HL survivors who reported 
spontaneous post-treatment fatherhood are the biological fathers of the born children.  
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 Information on fertility issues is important in clinical oncological practice, and 
fertility-saving tasks and the risk of post-treatment infertility should be discussed with 
patients the patients at risk before treatment is initiated. Females should be informed that both 
the treatment and their age at treatment influence their fertility potential. Females aged above 
30 years at diagnosis are at high risk of becoming infertile. They constitute a subgroup for 
which cryopreservation of ovarian tissue should be considered. Since males have the 
opportunity for pretreatment cryopreservation of semen, and as spermatogenesis usually 
recovers, their risk of potential infertility after treatment is less and easier to deal with. 
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8. Conclusions  
 
 
Part I 
• HL survivors had almost five-fold increased mortality compared to controls from the 
general population matched for age and gender. 
• The presence of chronic fatigue in the 1994-survey was not associated with increased 
mortality. 
• The highest mortality among the HL survivors was observed in the non-participants in 
the 1994-survey, which was unexpected.  
 
 
Part II 
• Almost one third of the male lymphoma survivors had endocrine hypogonadism 
defined as elevated LH and / or low testosterone, independent of FSH value. 
• Lymphoma survivors aged above 50 years at survey were about five times more likely 
to have endocrine hypogonadism compared to those aged less than 40 years at survey. 
• Except for the lymphoma survivors in the Med-NHL treatment group (mainly treated 
with eight or less courses CHOP-based chemotherapy), those from the other treatment 
groups had higher risk for endocrine hypogonadism compared to those treated with 
radiotherapy only or low gonadotoxic chemotherapy.  
 
• Compared to age matched controls from the general population, male lymphoma 
survivors reported reduced sexual function in the domain scores of erection, 
ejaculation and overall sexual satisfaction. 
• Among the male lymphoma survivors reduced sexual function was associated with 
increasing age, more emotional distress and reduced perception of physical health. 
• Male lymphoma survivors with low testosterone and / or elevated LH had impaired 
sexual function than those with normal gonadal hormones. 
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• About half of the HL survivors reported to have attempted post-treatment parenthood, 
with young age and childlessness at diagnosis being significantly associated with 
attempts of post-treatment parenthood. 
• Of those who had attempted post-treatment parenthood, about two thirds became 
parents spontaneously. 
• Type of treatment was significantly associated with achievement of post-treatment 
parenthood in both genders, with highest probabilities of achieveing children post-
treatment after radiotherapy only and low gonadotoxic chemotherapy. 
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9. Clinical implications and future perspectives 
 
 The finding of increased mortality in the non-responders compared to the responding 
HL survivors in the 1994-survey needs to be confirmed and explored by further examinations, 
also in other groups of cancer survivors. In addition, in our study the underlying cause of 
death was recorded, whereas comorbidities which may have contributed to death were not 
taken into account, which may give further information on the development of comorbidities 
in lymphoma survivors in future studies. 
 Few studies have been performed on mortality and causes of death after treatment for 
NHL, and such studies could be interesting to perform with the basis in the Lymphoma 
database at the NRH. In the future, one of the main questions is whether late adverse health 
affects and overall long-term survival after treatment for malignant lymphomas has been 
improved after the introduction of newer treatment strategies, such as the reduction of the 
radiotherapy fields in the treatment of HL in 1997.  
 The results of the study on gonadal hormones in male lymphoma survivors imply that 
these should be assessed regularly in male lymphoma survivors, especially after treatment 
with high-dose alkylating agents and HDT and in males 50 years and older, because low 
levels of testosterone may give symptoms as sexual problems, reduced energy and impaired 
vitality. If gonadal hormones indicate hypogonadism, further analyses and clinical evaluations 
should examine the need for testosterone substitution in order to avoid serious health 
problems in the future. To evaluate the effect of testosterone substitution in hypogonadal male 
lymphoma survivors more studies are needed.   
The mechanisms underlying reduced sexual function in lymphoma survivors should be 
explored in more details. Based on our findings in male lymphoma survivors, it would it be of 
clinical relevance to analyse factors related to impaired sexual function also in female 
lymphoma survivors. In order to offer malignant lymphoma survivors optimal follow-up care, 
further research on the effects of sexual counseling, hormonal treatments and lifestyle-
changes are needed.  
Studies on late-effects after treatment for malignant lymphoma should include 
prospective studies to a larger degree, with assessment of survivor outcomes pre- and post 
treatment. Longitudinal studies will provide data on the natural history / development of 
specific long-term effects after cancer treatment. As an example, to follow the natural course 
of both gonadal and sexual function in cancer survivors over time from diagnosis to post-
treatment would gather new information. In the aspects of fertility, longitudinal studies would 
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give information on for instance at what time point after treatment cancer survivors start to 
plan parenthood.  
Studies including genetic analyses could provide improved knowledge about the 
diseases itself but also about long-term effects after treatment for HL and NHL. Translational 
research may in addition to the usual “bench to bed”-view refer to the incorporation of new 
knowledge into the community (151), for instance on cancer survivorship issues . The best 
follow-up care of long-term lymphoma survivors for detection and eventual prevention of 
long-term effects is an issue of debate in today’s health care system. For the majority of the 
lymphoma survivors, regular controls by a general practioner may probably provide the best 
follow-up care, while subgroups of lymphoma survivors may need follow-up by oncologists 
or other medical specialists. 
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Abstract 
Background 
Negative health outcomes of chronic fatigue (CF) in disease-free cancer survivors are mainly 
unexplored. Aims of this study were to examine mortality and causes of death in Hodgkin’s lymphoma 
survivors (HLSs) compared to controls from the general population, and to explore if CF was 
associated with increased mortality. 
Methods 
HLSs (n=557) invited to participate in a survey on late effects in 1994 were divided into three groups: 
participants without CF (n=329), participants with CF (n=113), non-participants (n=98). Controls 
matched for gender and age were drawn from the general population (five per HLSs, n=2785). 
Observation time was calculated from January 1st 1994 until date of death or cut-off at January 1st 
2007. Kaplan-Meier plots were used for univariate analyses and Cox models for multiple covariates.  
Results  
Compared to controls HLSs had nearly five times higher mortality (HR=4.93; 95%CI:3.91-6.21) and 
the mortality rate of HLSs was higher than the rate of their controls for the entire observation 
period. Mortality was increased in all groups: participants with CF: HR= 4.85 (95%CI:3.02-7.77), 
participants without CF: HR=4.35 (95%CI: 3.16-6.00), non-participants: HR= 9.45 (95%CI:5.44-
16.41). 
Compared to the controls HLSs had over six times increased mortality of cancer (HR: 6.6, 95%CI: 
4.7-9.2) and almost five times increased mortality of cardiovascular diseases (HR: 4.9, 95%CI: 3.1-
7.9). 
Conclusions 
HLSs had almost five-time increased mortality compared to controls. CF was not associated with 
increased mortality rate. The high mortality among the non-participating HLSs indicates that serious 
health problems are underestimated in this group. This has implications for the interpretation of 
surveys in cancer survivors.  
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Introduction 
          Long-term survivors after Hodgkin’s lymphoma (HL) are at increased risk of different 
morbidities after treatment, such as second cancers, cardiovascular diseases, hormonal 
dysfunction and infertility (1-9). Previous studies have shown that Hodgkin’s lymphoma 
survivors (HLSs) also have increased mortality when compared to expected death rates in the 
general population (2, 10-12). Few studies have examined mortality in HLSs observed for 
more than 12 years (2). Patients treated for HL before the age of 41 years in the period 1965-
1987 (median follow-up 17.8 years, n=1261) were reported to have a 6.8 times higher relative 
risk (RR) of death from all causes other than HL compared to the general population (2). 
Another survey reported that the RR of mortality from all causes remained significantly 
elevated more than 20 years after treatment for stage IA-IIB HL (n=1080) (10). The most 
common causes of deaths are reported to be relapse of HL, second cancers, cardiovascular 
diseases and infections (2, 10). In addition, HLSs have been shown to have increased levels of 
fatigue persisting several years after treatment (13, 14).  
   The present study is based on a cohort of 557 HLSs included in a survey in 1994 on 
long-term effects including the presence of chronic fatigue (CF) (15, 16). The HLSs were 
treated at the Norwegian Radium Hospital (NRH) from 1971-1991 and were considered to be 
in complete remission when included in the survey in 1994. The main finding among the 
responding HLSs was that 26% had CF after a median observation time of 12 years, compared 
to 11% of controls representative of the general Norwegian population (16). Uncertainty 
exists as to the causes of CF in HLSs, and one might speculate whether it reflects aspects of 
the disease itself such as altered cytokine levels or immune dysfunction which can exert long-
term negative health effects. Knowledge about possible negative impact of CF upon somatic 
health outcomes is lacking, and no study has investigated the association between CF and 
future significant health events such as mortality in cancer survivors. In addition, to our 
knowledge, no studies in cancer survivors have investigated mortality in participants versus 
non-participants in questionnaire surveys.       
Thus, the main objectives of this study were as follows: 
1. To examine mortality and causes of death in a defined cohort of HLSs who were 
considered to be disease-free when surveyed in 1994 (15, 16) and compare the 
mortality to a control group from the general population matched for age and gender. 
2. To examine whether HLSs with CF in 1994 display increased mortality compared to 
HLSs without CF and the non-participants from the same survey (16).  
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Patients and Methods 
Subjects 
          The eligibility criteria for the cross-sectional survey in 1994 were HLSs treated at the 
NRH from 1971-1991, aged 15-61 years at diagnosis and aged 19-74 at the time of the survey, 
alive and in complete remission by the end of 1993, with only a small percentage of the 
patients treated for relapse (15, 16).  In the period 1970-1980 the treatment of HL in Norway 
was centralized to the NRH, and 92% of patients aged 15-39 years and 80% of patients aged 
40-59 years were admitted to the hospital. Since 1981 four other national oncological centers 
gradually began to treat HL (17). After 1985 all HL patients from a defined region 
constituting about 50% of the Norwegian population have been referred to the hospital. The 
treatment of HL at the NRH in the period 1971-1991 followed international guidelines and 
have been described previously (1, 15, 16, 18). Stage I/II were treated with extended radiation 
fields (Mantle/Inverted-Y field) alone or after chemotherapy. Stage III/IV was treated with 
eight chemotherapy courses, with radiation to sites of initial bulky tumor or residual masses 
from 1980. Chemotherapy was given as MVPP/ChlVPP, gradually replaced by ABVD from 
1985. 
 In 1994, 557 patients were contacted by mail and 459 returned the completed 
questionnaire. The main outcome was self-reported health status including fatigue (16, 19, 
20). Fatigue was assessed by Fatigue Questionnaire (FQ) (21) which measures physical fatigue 
(7 items) and mental fatigue (4 items). The sum of all items is designated total fatigue. Two 
additional items cover the duration and extent of fatigue. The prevalence of CF was assessed as 
described and required substantial fatigue for 6 months or more at time of assessment (16).  
 Based on findings from the 1994 survey the HLSs were categorized in three groups: 
participants without CF (No-CFgroup,n=329), participants with CF (CFgroup,n=113), and 
non-participants who did not return the questionnaire (Non-Partgroup,n=98), 17 patients had 
invalid FQ and were not categorized. Medical information on the HLSs was retrieved from 
the lymphoma database of the NRH. Age at diagnosis was divided into four groups: 15-21 
years, 22-30 years, 31-40 years, 41-60 years.  
 
Controls 
          A control group was constructed by randomly drawing five controls per patient from 
the general population matched for gender and age. The draw was performed by Statistics 
Norway (SSB). The controls had to be alive on 31.12.1993, as were the HLSs at inclusion in 
the 1994-survey. For both the HLSs and the controls date of death and causes of death were 
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retrieved from the Statistics for Causes of Deaths, Statistics Norway (SSB). Causes of deaths 
were categorized into three groups: 1: tumor (all malignant diagnosis), 2: cardiovascular 
disease, 3: other (including infections, diabetes, pulmonal diseases, gastrointestinal diseases, 
traumas, diseases in the urinary system, diseases in the musculo-skeletal system, psychiatric 
diseases. In case of deaths from tumors, these were subdivided in two: 1: malignant 
lymphomas and 2: other malignancies, including solid tumors, multiple myeloma and 
leukemias. 
 
Statistics 
 Continuous variables were described using median and range, whereas categorical data 
were described with proportions. Crude differences in categorical variables were assessed 
with Chi-square tests, whereas continuous variables were analyzed with Mann-Whitney-
Wilcoxon tests. Observation time for survival analyses was calculated from January 1st 1994 
until date of death or to cut-off at January 1st 2007. Crude cumulative probability of survival 
was calculated using the Kaplan-Meier method and the groups compared with log-rank tests. 
Cox proportional hazard regression models stratified by the matched group were used for 
univariate and multivariate analyses. The proportionality of hazards assumption was 
investigated using log minus log plots. 
 The three groups of HLSs were compared to the matched control groups in separate 
analyses. Considering the HLSs only, possible predictors of death were first investigated in 
univariate analyses. Secondly, statistically significant variables (age at diagnosis, period of 
treatment, treatment and patient group (No-CFgroup, CFgroup, Non-Partgroup)) were entered 
into a multiple model. 
 The cumulative probability of dying was computed using a competing risk approach 
(22) with death causes divided into four categories:1: malignant lymphomas; 2:other cancers; 
3:cardiovascular diseases and 4: other causes of death. 
 A p-value 0.05 (two-sided) was considered statistically significant. All analyses were 
performed with SPSS 16 and Stata version 10. 
 
Ethical considerations 
          The Regional Committee for Medical Research Ethics, Health Region South, Norway 
approved the study.  
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Results 
Patients’ characteristics 
          Of the 557 HLSs who were approached in 1994, 43% were female. Median age at 
diagnosis was 30 years (range 15-60) and median age at survey in 1994 was 43 years (range 
19-74) (Table 1). The median observation time from diagnosis to the survey in 1994 was 12.2 
years (range 2.3-23.0 years). Seventy-eight percent were treated with mantle field or 
mediastinal radiotherapy with or without chemotherapy. The CFgroup had a higher median 
age at diagnosis than the two other subgroups (p<0.01), whereas there were no statistically 
significant differences in gender, period of diagnosis, primary stage or treatment among the 
three groups of HLSs. For further details on the patient cohort, see previous publications (15, 
16). 
 
All cause mortality in HLSs versus controls 
          By January1st 2007 death had occurred in 149 of the 557 HLSs (27%), 72 deaths in the 
No-CFgroup (22%), 35 deaths in the CFgroup (31%) and 38 deaths in the Non-Partgroup 
(39%). In comparison, 197 (7%) deaths had occurred among the controls (Table 1). Mortality 
among all HLSs was significantly increased compared to the controls, the HLSs were almost 
five-times more likely to die (HR: 4.93 [95% CI: 3.91-6.21]). The mortality rate of patients 
was higher than the rate of their controls throughout the entire observation period Table 2 
and Figure 1a.     
          When comparing each patient group to its matched control group, the CFgroup had an 
increased mortality rate of 4.85 [95%CI: 3.02-7.77], whereas the No-CFgroup had an 
increased mortality rate of 4.35 [95%CI: 3.16-6.00]. The comparable figures for the Non-
Partgroup were 9.45 [95% CI: 5.44-16.41] (Table 2 and Figure 1b).  
 
Factors associated with mortality within the HLSs 
        In univariate analyses both the CFgroup (HR: 1.54, [95%CI: 1.03-2.31]) and the Non-
Partgroup (HR: 2.04, [95%CI: 1.37-3.02]) had increased mortality rate compared to No-
CFgroup (Table 3). When comparing overall mortality ratio in the Non-Partgroup to all 
participants (with and without CF) the HR for the Non-Partgroup was almost doublet (HR: 1.8 
[95%CI: 1.24-2.60]).  
 Patients treated with mantle field or mediastinal radiotherapy had a two-fold increased 
mortality rate compared to patients treated with chemotherapy only (HR: 2.02, [95%CI: 1.09-
 7
3.74]). Compared to those diagnosed in the period 1981-1990, patients diagnosed in 1971-
1980 had increased mortality rate (HR: 2.46, [95% CI: 1.76-3.44]).  
          Multivariate analysis revealed that the Non-Partgroup had a two-fold increased risk of 
mortality (HR: 2.05, [95%CI: 1.37-3.07]) compared to the No-CFgroup. No statistically 
significant difference was observed between the participants with and without CF. Treatment 
group remained significant with patients treated with radiotherapy with or without 
chemotherapy having about three times higher mortality risk than those treated with 
chemotherapy only. Patients diagnosed before 1981 had increased risk of mortality compared 
to those diagnosed from 1981 onwards (HR: 1.56, [95%CI: 1.10-2.27]). 
 
Causes of deaths 
  Among the HLSs 83 of the 149 (56%) deaths were caused by malignant disease and 
36 (24%) were caused by cardiovascular diseases. Among the controls 41% (81/197) of the 
deaths were caused by malignant diseases and 25% (50/197) by cardiovascular diseases 
(Table 4a). Overall, the risk of dying of cancer or all other causes was always higher for 
HLSs compared to their controls, as depicted in Figure 2. Compared to the controls, the HLSs 
had more than six times increased mortality of cancer (HR: 6.6, 95%CI 4.7-9.2) and almost 
five times increased mortality of cardiovascular disease (HR: 4.9, 95%CI: 3.1-7.9) (Table4b). 
No differences between the predefined patient groups in regard to causes of deaths were 
observed (data not shown). 
  Among the HLSs who died of malignant diseases, 33 of these deaths were caused by 
malignant lymphomas (of which 21 by HL) and 50 by other cancer types (pulmonary cancer: 
n=20, cancer in the gastrointestinal tract: n=11, breast cancer: n = 3, leukemia / multiple 
myoloma: n=3). Deaths due to malignant lymphomas occurred significantly earlier than 
deaths by secondary solid tumors (data not shown).  
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Discussion 
 In the present study mortality and causes of death were examined in an unselected 
cohort of disease-free HLSs included in a previous questionnaire survey (16). The present 
study provides new information on mortality and causes of death in HLSs due to a 
substantially longer follow-up period than previous studies (10-12), with a median 
observation time of 12 years from diagnosis to the survey in 1994, and thereafter observation 
until 2007. Compared to the controls, the HLSs had almost five times higher mortality, and 
the mortality rate of patients was higher than the rate of their controls throughout the entire 
observation period.  In the multivariate analysis, the presence of CF was not significantly 
associated with increased mortality among the HLSs who participated in the 1994-survey, but 
the Non-Partgroup displayed a two-fold increased mortality compared to the No-CFgroup.  
The cross-sectional nature of the 1994-survey makes the patient group biased with 
regard to survival compared to other studies on mortality in HLSs, because only HLSs alive in 
1994 were included. Nevertheless, the survival in the 1994 cohort after 13 years of additional 
observation time was 73%, which is comparable to figures reported from other studies (2, 11). 
A ten year overall survival of 75% was reported when investigating 1261 patients treated for 
HL in the period 1965-1987 (2). However, that patient cohort included only patients treated at 
age less than 41 years at diagnosis, whereas our sample included patients up to 60 years at 
diagnosis (2). Ng et al found a somewhat higher 15-year survival rate of 84% in their patients 
treated for early-stage HL at age 50 or younger (10).  
 There was almost a five-fold increase in mortality risk among the HLSs compared to 
the control group from the general population. This number is slightly lower than the 
increased RR of mortality of 6.4 and 6.8 found in other studies (2, 10). In comparison, 
Provencio et al reported the mortality rate among patients treated for HL to be >10-fold higher 
than mortality rates from the general population (11). Methodologically, these earlier studies 
explored the standardized mortality ratio; the ratio between the observed deaths in the cohort 
and the expected number of deaths if the cohort had the same mortality rate as the general 
population (2, 10, 11).  In contrast, our control group was constructed by drawing five persons 
per HLSs from the general population matched for age and gender, and both the HLSs and 
controls were followed to either death or time for cut-off. The use of matched controls 
selected from the general population provides an intuitively understandable interpretation of 
the results. Moreover, having 5 controls per patient ensured a high level of efficiency and 
precision of our estimates (23). 
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  At inclusion in the 1994-survey, the patients were considered to be in complete 
remission. However, the observation time from diagnosis to inclusion in 1994 had a wide time 
span from 2-23 years (median 12 years) and makes the patient group heterogeneous, with 
patients with the shortest observation time from diagnosis to the 1994-survey having higher 
risk for relapse than patients with longer observation time.  
 Of particular interest, a two-fold increased risk of mortality among the Non-Partgroup 
compared to the No-CFgroup was observed. To our knowledge, such an association between 
the willingness/ability to respond to a questionnaire survey and a central health outcome has 
not been described in cancer survivors earlier. However, epidemiological studies have 
indicated impaired health status and higher mortality in groups of non-responders (24, 25). 
The observation of increased mortality among the Non-Partgroup indicates that impaired 
health may explain why some HLSs did not respond to the questionnaire survey in 1994. A 
possible burden in the Non-Partgroup as to having more symptoms and impaired physical 
health may imply that adverse health effects in HLSs might be underestimated in follow-up 
surveys. This finding needs to be confirmed and explored by further examinations, also in 
other groups of cancer survivors. 
 In univariate analysis, increased mortality in the CFgroup compared to the No-
CFgroup was observed. However; this difference disappeared in the multivariate analysis, 
probably reflecting confounding by age, since, in 1994, the CFgroup were significantly older 
than the No-CFgroup. The finding of similar mortality in HLSs with and without CF is of 
clinical importance, as it indicates that CF itself is not associated with life-threatening somatic 
morbidity. Theoretically, HLSs with CF might have had more intense follow-up due to their 
condition than the HLSs without CF with possible beneficial effects upon morbidity and 
mortality. However, no special programs for HLSs with CF have been running during the 
observation period, and in our opinion a possible bias related to this can therefore be 
excluded.   
 Patients diagnosed in the period 1971-1980 had increased mortality rate compared to 
those diagnosed in the period 1981-1991 both in univariate and multivariate analyses, which 
is comparable to earlier findings (11). This observation may be due to more toxic treatment in 
the first period, particularly caused by the use of larger radiation fields, and/or better treatment 
options in the latter period. Another explanation is improved histopathological diagnosis; 
some lymphomas classified as HL in the earliest period, especially of the lymphocyte depleted 
and unclassified subtypes in the elderly (considered to be associated with poor prognosis), 
probably have been classified as NHL during the second period (17). 
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 Malignant diseases and cardiovascular diseases were the most frequent causes of 
deaths among the HLSs, which is similar to earlier reports (2, 10). Mortality of cancer was 
more than six times higher in HLSs compared to the control group, and almost five times 
higher for cardiovascular diseases. This is comparable to the RR of deaths resulting from solid 
tumors reported to be 6.6 and cardiovascular disease reported to be 6.3 in 1261 patients 
treated for HL before age 41 (2). In comparison, Ng et al reported the RR of excess mortality 
from second tumors to be 11.2  and 3.2 from cardiovascular diseases in their cohort of 1080 
HLSs (10).  
   The treatment of the patients in the described cohort is no longer standard therapy, as 
the treatment for HL has been modified in order to avoid long-term effects without reducing 
the very good survival rates. Mantle field irradiation is no longer used as standard therapy, 
and for chemotherapy, MOPP-like regimens have to a large extent been abandoned. 
Nevertheless, it is of importance to study the morbidity and mortality after treatment with 
these regimens because a large number of survivors after such treatment are still alive. In 
addition, patients today still receive radiotherapy, albeit to smaller volumes and with lower 
doses, and chemotherapy regimens used today, such as ABVD and BEACOPP, still contain 
many of the same compounds as did earlier regimens. In a recently published study 
comparing overall survival (OS) after treatment for advanced stage HL (median follow-up 
111 months), OS was significantly improved after treatment with escalated-dose BEACOPP 
compared to COPP/ABVD and standard BEACOPP (26).  However, a higher number of acute 
myeloid leukemia and myelodysplastic syndrome in the dose-escalated BEACOPP arm was 
observed, whereas there were no differences in the total number of secondary malignancies 
between the treatment arms (26).  This emphasizes the importance of clinicians being aware 
of possible long-term complications after curative treatment for HL and provides the best 
follow-up care as possible. 
  Overall, we showed that in this cohort of HLSs, assumed to be in complete remission 
in 1994, the overall mortality risk was almost five times higher than for matched controls 
from the general population. This raises the question whether the total long-term mortality is a 
better estimate of successful treatment of HL, than specific mortality of HL. 
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Table 1. 
Patients characteristics, Hodgkin lymphoma sample n=557, Control sample n=2785. 
 
 
 
 
All HLSs 
 
N=557 
 
No-CFgroup* 
 
N=329 
 
CFgroup* 
 
N=113 
 
Non-partgroup* 
 
N=98 
 
Controls 
 
N=2785 
 
Age at diagnosis (years)1 
Median (range) 
    
 
 
30    (15-60) 
 
 
28     (15-60) 
 
 
33    (15-60) 
 
 
28    (15-60) 
 
 
Age at survey 1994 (years) 2 
Median (range) 
   
 
 
43    (19-74) 
 
 
41     (19-74) 
 
 
46     (21-74) 
 
 
41    (20-72) 
 
 n (%) n (%) n (%) n (%) n (%) 
Gender 
   Male 
   Female 
 
320  (57) 
237  (43) 
 
187   (57) 
142   (43) 
 
 
60    (53) 
53    (47) 
 
65    (66) 
33    (34) 
 
 
Period of diagnosis 
   1971 - 1980 
   1981 – 1991 
 
 
242   (43 ) 
315   (57 ) 
 
 
132   (40 ) 
197   (60 ) 
 
 
50    (44 ) 
63    (56 ) 
 
 
50    (51 ) 
48    (49 ) 
 
 
Treatment group    
1. Chemotherapy only 
 
2. Radiotherapy including  
mediastinum ± chemotherapy 
 
3.  Radiotherapy not including 
mediastinum  ±  chemotherapy 
 
 
 
73 (13) 
 
429 (78) 
 
 
45 (8) 
 
 
40 (12) 
 
256 (80) 
 
 
26 (8) 
 
 
 
15 (13) 
 
88 (79) 
 
 
9 (8) 
 
 
16 (17) 
 
73 (76) 
 
 
7 (7) 
 
 
Primary stage 
   I / IIA 
   I / IIB 
   III / IV A 
   III / IV B 
 
 
 
 
269    (48) 
67      (12) 
104    (19) 
117    (21) 
 
 
165   (50) 
32     (10) 
61     (19) 
71     (22) 
 
 
50    (44) 
21    (19) 
24    (21) 
18    (16) 
 
 
45    (46) 
13    (13) 
16    (16) 
24    (25) 
 
 
Mortality3 
   Alive 
   Dead 
 
 
 
408   (73) 
149   (27) 
 
 
257   (78) 
 72    (22) 
 
 
78    (69) 
35    (31) 
 
 
60    (61) 
38    (39) 
 
 
2588  (93) 
  197  (7)    
 
CF:chronic fatigue 
No-CF group: Participants without CF 
CF group: Participants with CF 
Non-Partgroup: Non-participants 
1participants with CF higher median age at diagnosis than the two other subgroups of HLSs (p<0.01). 
2 participants with CF higher median age at survey 1994 than participants without fatigue (p<0.001) 
3 Mortality at cut-off January 1st 2007 
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Table 2. 
All cause mortality in Hodgkin lymphoma sample versus controls. 
 
 
Hodgkin lymphoma sample versus controls 
 
HR 
 
 
95% CI 
 
Controls (n=2785) 
 
reference 
 
 
HLSs (n=557) 
 
4.93 
 
3.91-6.21 
 
Each patient group versus the equivalent 
control group 
 
HR 
 
 
95% CI 
 
Non-Partgroup (n=98) 
 
9.45 
 
5.44-16.41 
 
CF group (n=113) 
 
4.85 
 
3.02-7.77 
 
No-CF group (n=329) 
 
4.35 
 
3.16-6.00 
 
 Non-Partgroup: Non-participants 
 CFgroup: Participants with CF 
 No-CF group: Participants without CF 
 CF:chronic fatigue 
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Table 3. 
Uni- and Multivariate analyses of predictors for deaths among HLSs (n=540) 
 
Within the cohort of HLSs (n=540) 
  
Univariate Cox model 
 
Multivariate Cox model 
 
Variable 
 
 
HR 
univariate COX 
 
95% CI 
 
 
HR  
multivariate Cox 
 
95%CI 
 
Patient groups     
 
No-CFgroup   
 
reference 
 
 
reference 
 
 
CFgroup  
 
1.54 
 
1.03-2.31 
 
1.31 
 
0.87-1.97 
 
Non-Partgroup 
 
2.04 
 
1.37-3.02 
 
2.05 
 
1.37-3.07 
 
Treatment groups 
 
 
  
 
 Chemotherapy only  
 
reference 
 
 
reference 
 
 
 Radiotherapy including 
mediast 
 
2.02 
 
1.09-3.74 
 
2.94 
 
1.29-6.97 
 
 Radiotherapy not 
including mediast 
 
1.88 
 
0.81-4.33 
 
3.00 
 
1.56-5.53 
 
Period of diagnosis 
 
 
  
 
1971 – 1980  
 
2.46 
 
1.76-3.44 
 
1.56 
 
1.10-2.27 
 
1981 - 1991 
 
reference 
  
reference 
 
 
Age at diagnosis 
 
 
  
 
15-21 years 
 
reference 
  
reference 
 
 
22-30 years 
 
2.78 
 
1.37-5.62 
 
2.44 
 
1.15-5.20 
 
31-40 years 
 
4.71 
 
2.37-9.36 
 
3.87 
 
1.83-8.20 
 
41-60 years 
 
11.19 
 
5.71-21.94 
 
11.55 
 
5.54-24.09 
 
 Non-Partgroup: Non-participants 
 CFgroup: Participants with CF 
 No-CF group: Participants without CF 
CF:chronic fatigue 
HLSs:Hodgkin’s lymphoma survivors 
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Table4a. Causes of deaths in HLSs (n=557) and controls (n=2785). 
 
 
Group 
 
 
Malignant 
disease 
 
 
Cardiovascular 
disease 
 
Other 
 
Controls 
(N=2785) 
Dead by Jan 1st 2007 
n=197 (7%) 
 
% of this group 
 
 
 
81 
(3%) 
 
 
 
50 
(2%) 
 
 
 
66 
(2%) 
 
 
 
83 
(15%) 
 
 
 All HLSs (N=557) 
 
Dead by Jan 1st 2007      
n=149 
(27%) 
 
% of this group 
Malignant 
Lymphoma 
 
33  
21 HL / 12 NHL 
Other 
cancers 
 
50  
 
 
 
36 
(6%) 
 
 
 
30 
(5%) 
 
 
 
 
46 (14%) 
 
 No-CFgroup  
N=329 
Dead by Jan 1st 2007      
n=72 (22%) 
 
% of this group 
 
Malignant 
Lymphoma 
 
19  
Other cancers 
 
 
27  
 
 
 
 
16 (5%) 
 
 
 
 
10 (3%) 
 
 
15 (13%) 
 
    
CFgroup  
N=113 
Dead by Jan 1st 2007      
n=35 (31%) 
 
% of this group 
Malignant 
Lymphoma 
 
3  
Other cancers 
 
 
12  
 
 
11 (10%) 
 
 
9 (8%) 
 
 
20 (20%) 
 
  
Non-Partgroup 
N=98 
Dead by Jan 1st 2007      
n=38 (39%) 
 
% of this group 
Malignant 
Lymphoma 
 
10  
Other cancers 
 
 
10  
 
 
7 (7%) 
 
 
11 (11%) 
 
 Non-Partgroup: Non-participants 
 CF group: Participants with CF 
 No-CF group: Participants without CF 
CF: chronic fatigue 
HLSs: Hodgkin’s lymphoma survivors 
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Table4b  
HR and 95%CI for the various causes of deaths comparing all HLSs (n=557) to controls (n=2785). 
Hodgkin lymphoma 
sample versus controls 
 
HR 
 
95% CI 
 
p-value 
 
Cancer 
 
6.6 
 
4.7-9.2 
 
<0.001 
 
Cardiovascular disease 
 
4.9 
 
3.1-7.9 
 
<0.001 
 
Other 
 
2.9 
 
1.9-4.7 
 
<0.001 
 
HLSs: Hodgkin’s lymphoma survivors 
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Figure 1a 
 
 
 
 
 
 
 
 
 
Figure1a 
Cumulative overall mortality rate in Hodgkin lymphoma sample (HLSs, n=557) and controls (n=2785) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HLSs 
Ctrs 
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Figure1b 
 
 
 
 
 
 
 
Legends Figure 1b. 
Cumulative mortality rate in HLSs related to patient group and the relevant control groups.  
All patient groups displayed increased mortality compared to their controls (p<0.001). 
HLSs:  I: Participants without chronic fatigue (CF) n=329 
II: Participants with CF, n =113 
III: Non participants, n=98 
Ctrs: controls 
  CtrsI: controls to participants without CF, n=1645 
 CtrsII: controls to participants with CF, n=565 
 CtrsIII: controls to non-participants, n=490 
 
 
 
 
 
 
 
 
Ctrs 
HLSs 
I 
II 
III 
CtrsI 
CtrsII 
CtrsIII 
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Figure2 
 
 
Figure2. 
Plot of competing causes of deaths among HLSs and controls. 
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